Original Article
Daptomycin versus Standard Therapy for Bacteremia and Endocarditis Caused by Staphylococcus aureus
N Engl J Med 2006; 355:653-665August 17, 2006
- Abstract
Background
Alternative therapies for Staphylococcus aureus bacteremia and endocarditis are needed.
Methods
We randomly assigned 124 patients with S. aureus bacteremia with or without endocarditis to receive 6 mg of daptomycin intravenously per kilogram of body weight daily and 122 to receive initial low-dose gentamicin plus either an antistaphylococcal penicillin or vancomycin. The primary efficacy end point was treatment success 42 days after the end of therapy.
Results
Forty-two days after the end of therapy in the modified intention-to-treat analysis, a successful outcome was documented for 53 of 120 patients who received daptomycin as compared with 48 of 115 patients who received standard therapy (44.2 percent vs. 41.7 percent; absolute difference, 2.4 percent; 95 percent confidence interval, −10.2 to 15.1 percent). Our results met prespecified criteria for the noninferiority of daptomycin. The success rates were similar in subgroups of patients with complicated bacteremia, right-sided endocarditis, and methicillin-resistant S. aureus. Daptomycin therapy was associated with a higher rate of microbiologic failure than was standard therapy (19 vs. 11 patients, P=0.17). In 6 of the 19 patients with microbiologic failure in the daptomycin group, isolates with reduced susceptibility to daptomycin emerged; similarly, a reduced susceptibility to vancomycin was noted in isolates from patients treated with vancomycin. As compared with daptomycin therapy, standard therapy was associated with a nonsignificantly higher rate of adverse events that led to treatment failure due to the discontinuation of therapy (17 vs. 8, P=0.06). Clinically significant renal dysfunction occurred in 11.0 percent of patients who received daptomycin and in 26.3 percent of patients who received standard therapy (P=0.004).
Conclusions
Daptomycin (6 mg per kilogram daily) is not inferior to standard therapy for S. aureus bacteremia and right-sided endocarditis. (ClinicalTrials.gov number, NCT00093067.)
Media in This Article
Figure 1
Comparison of the Rates of Success of Daptomycin and Standard Therapy for Staphylococcus aureus Bacteremia and Endocarditis.Table 1
Characteristics of Patients in the Modified Intention-to-Treat Population.Article Activity
- Article
Staphylococcus aureus is a leading cause of bacteremia1,2 and endocarditis.3,4 S. aureus bacteremia is associated with serious complications, including endocarditis, in 30 to 40 percent of cases.5,6 Treatment options for bacteremia and endocarditis caused by S. aureus, particularly methicillin-resistant S. aureus (MRSA), are limited. Vancomycin, the standard therapy for bloodstream infections attributable to MRSA, has been associated with suboptimal outcomes.7-10 New agents for the treatment of S. aureus bacteremia and endocarditis are needed.
Daptomycin is a cyclic lipopeptide antibiotic that is rapidly bactericidal in vitro against most clinically relevant gram-positive bacteria, including S. aureus.11-14 Daptomycin is approved for the treatment of complicated skin and skin-structure infections attributable to gram-positive organisms at a dose of 4 mg per kilogram of body weight intravenously per day,15 but its efficacy in the treatment of S. aureus bacteremia and endocarditis and its safety at higher doses have not been established. We assessed the efficacy and safety of daptomycin as compared with standard therapy for S. aureus bacteremia and endocarditis.
Methods
Study Design
This open-label, randomized trial was conducted between August 28, 2002, and February 16, 2005. The institutional review board at each site approved the protocol, and all patients or their authorized representatives provided written informed consent. Eligible patients were 18 years of age or older and had one or more blood cultures that were positive for S. aureus within two calendar days before initiating study medication. Patients were ineligible if they had a creatinine clearance of less than 30 ml per minute, known osteomyelitis, polymicrobial bacteremia, or pneumonia. Full exclusion criteria are listed in the Supplementary Appendix, available with the full text of this article at www.nejm.org.
The adjudication committee of five infectious-disease experts (Drs. Abrutyn, Corey, Cosgrove, Fowler, and Karchmer) reviewed the data from each patient to establish the diagnosis and outcome. The committee was unaware of patients' treatment assignments.
Definitions
The diagnosis at baseline was determined with the use of the modified Duke criteria.16 The adjudication committee determined final diagnoses (Table 1Table 1
Characteristics of Patients in the Modified Intention-to-Treat Population.). Uncomplicated bacteremia was defined by the isolation of S. aureus from enrollment blood cultures in patients without endocarditis and without evidence of hematogenous spread. Patients with such infections received medication for a minimum of 10 to 14 days. In patients without definite endocarditis, complicated bacteremia was defined by the isolation of S. aureus from blood cultures on at least two days through study day 5, the presence of spread of infection, or infection involving prostheses not removed within four days. Such patients received medication for a minimum of 28 to 42 days. Uncomplicated right-sided endocarditis was defined as definite or possible16 methicillin-susceptible S. aureus (MSSA) endocarditis in the absence of predisposing abnormalities or active infection of the mitral or aortic valve in a patient with active injection-drug use, a serum creatinine level of less than 2.5 mg per deciliter (221 μmol per liter), and no evidence of extrapulmonary sites of infection. Patients with uncomplicated MSSA right-sided endocarditis received medication for a minimum of 14 to 28 days. Complicated right-sided endocarditis was defined as definite or possible16 endocarditis in the absence of predisposing abnormalities or active infection of the mitral or aortic valve, with extrapulmonary sites of infection, a serum creatinine level of at least 2.5 mg per deciliter, MRSA bacteremia, or the absence of injection-drug use. Patients with such infections were treated for a minimum of 28 to 42 days. Left-sided endocarditis was defined according to the criteria of Li et al.16 Patients with such infections received medication for a minimum of 28 to 42 days.The intention-to-treat population included all randomized patients. All patients in the intention-to-treat group who received at least one dose of the study medication were included in the safety analyses. The modified intention-to-treat population included all randomized patients who received at least one dose of study medication except those with a high likelihood of left-sided endocarditis who were enrolled before a protocol amendment allowing their inclusion. The per-protocol population included all patients in the modified intention-to-treat group with documented adherence to the protocol (Figure 1 of the Supplementary Appendix). Unless otherwise specified, all results presented are based on the modified intention-to-treat population, the primary efficacy population.
Patients were considered to have clinical failure if they had no response to the study drug on the basis of ongoing signs and symptoms of infection. Patients were considered to have microbiologic failure if they had persistent or relapsing S. aureus infection, defined as either ongoing positive cultures leading to discontinuation of the study drug or subsequent isolation of S. aureus of the same strain type after apparent clinical improvement.
Randomization, Treatment, and Monitoring
Patients were randomly assigned with the use of a block randomization schedule to receive either daptomycin or standard therapy; this centralized computer-generated schedule was designed to achieve a 1:1 ratio of patients, stratified according to investigative site.
Patients received daptomycin (Cubicin, Cubist Pharmaceuticals) (6 mg per kilogram of body weight intravenously once daily) or standard therapy with either vancomycin (1 g every 12 hours with appropriate dose adjustment) or an antistaphylococcal penicillin (nafcillin, oxacillin, or flucloxacillin) (2 g every 4 hours), depending on the susceptibility of the causative strain to methicillin. The duration of therapy was determined by the investigator on the basis of the working diagnosis. All patients who were randomly assigned to standard treatment and patients with left-sided endocarditis who were assigned to daptomycin were to receive gentamicin (1 mg per kilogram intravenously every eight hours or adjusted on the basis of renal function) for the first four days.
The investigators evaluated patients at baseline, at the end of therapy, and 42 days after the end of therapy (at the test-of-cure visit). Blood cultures were obtained daily until they were negative, as well as at the end of therapy and 42 days after the end of therapy (Figure 1 of the Supplementary Appendix). Patients were required to undergo transesophageal echocardiography within five days after starting the study medication. All echocardiograms were reviewed by an independent expert unaware of the patient's treatment assignment; these results were used in all analyses.
An independent data and safety monitoring committee was established to regularly review the data and make recommendations regarding continuation of the study.
Clinical Outcomes
The primary outcome was the clinical success rate in each of the two treatment groups in the modified intention-to-treat population at the visit 42 days after the end of therapy. Failure at this visit was defined as clinical failure, microbiologic failure, death, failure to obtain blood culture, receipt of potentially effective nonstudy antibiotics, or premature discontinuation of the study medication because of clinical failure, microbiologic failure, or an adverse event.
Microbiologic Methods
The species of all isolates was identified, and each isolate was tested for antimicrobial susceptibility by a central laboratory with the use of accepted interpretative criteria.17 A minimal inhibitory concentration (MIC) of at least 2 μg of daptomycin per milliliter was considered to indicate a nonsusceptible isolate of S. aureus. S. aureus isolates from patients with persistent or recurrent infection were evaluated with repeated susceptibility testing and pulsed-field gel electrophoresis.
Statistical Analysis
Efficacy Assessments
In this noninferiority trial, the 95 percent confidence interval for the difference in success rates (daptomycin minus standard therapy) was calculated on the basis of the normal approximation to the binomial distribution. The noninferiority test was based on the lower bound of the confidence intervals being within the prespecified noninferiority margin of 20 percent and the upper bounds containing 0 percent. Assuming 65 percent efficacy in both treatment groups, a statistical power of 80 percent, and a one-sided significance level of 0.025, we estimated that 90 patients would need to be enrolled in each treatment group in the modified intention-to-treat population in order to test the null hypothesis (that the treatments differed by at least 20 percent). All reported P values were two-sided and not adjusted for multiple analyses.
Safety Assessments
The incidence of adverse events was compared between treatment groups with the use of Fisher's exact test. Changes in laboratory values, in particular, changes in serum creatine kinase and creatinine clearance, were evaluated. Creatinine clearance was calculated at baseline and at regular intervals thereafter according to the Cockcroft–Gault formula.18
The study was designed by the sponsor (Cubist Pharmaceuticals) with the assistance of Drs. Chambers, Fowler, and Karchmer. Data were held and analyzed by the sponsor. However, the authors had complete and unfettered access to the data and vouch for the veracity and completeness of the data and analyses used for this article.
Results
Patients
Of the 246 randomized patients, 10 (6 assigned to daptomycin and 4 assigned to standard therapy) did not receive the study drug (Figure 1 of the Supplementary Appendix); thus, 236 — 120 assigned to daptomycin and 116 assigned to standard therapy — were treated at 44 sites in four countries and represent the population used in the safety analyses. These 10 patients plus 1 patient who was treated with standard therapy and who enrolled before the amendment to allow patients with a high likelihood of left-sided endocarditis were excluded from the modified intention-to-treat population (120 assigned to daptomycin and 115 assigned to standard therapy). Risk factors for S. aureus infection were similar in the two groups (Table 1). Clinical evidence of the systemic inflammatory response syndrome was present in 89 of 120 patients treated with daptomycin (74.2 percent) and in 87 of 115 patients treated with standard therapy (75.7 percent). The median duration of therapy was 14 days for daptomycin and 15 days for standard therapy (including early discontinuations). Gentamicin was administered to 107 of 115 patients in the standard-therapy group (93.0 percent) and to 1 patient in the daptomycin group (0.8 percent) for a median of four days. At entry, 75.0 percent of the daptomycin group and 79.1 percent of the standard-therapy group met modified Duke criteria for definite or possible endocarditis. The final diagnoses were distributed similarly in the treatment groups (Table 1). MRSA was isolated from 45 of 120 patients who were treated with daptomycin (37.5 percent) and 44 of 115 patients who were treated with standard therapy (38.3 percent).
Outcome
A successful outcome was documented 42 days after the end of therapy for 53 of 120 patients in the daptomycin group, as compared with 48 of 115 patients in the standard-therapy group (44.2 percent vs. 41.7 percent; absolute difference, 2.4 percent; 95 percent confidence interval for the difference, −10.2 to 15.1 percent). The lower limit of the 95 percent confidence interval was within the prespecified margin of −20 percent; thus, daptomycin was not inferior to standard therapy. Differences in success rates were similar across all of the prespecified analyses (Table 2Table 2
Outcomes 42 Days after the End of Therapy, According to Prespecified Diagnostic Categories. and Figure 1Figure 1Comparison of the Rates of Success of Daptomycin and Standard Therapy for Staphylococcus aureus Bacteremia and Endocarditis.). Success rates favored daptomycin over vancomycin among patients who were infected with MRSA (44.4 percent for daptomycin vs. 31.8 percent for standard therapy, P=0.28) but were higher among patients receiving standard therapy for MSSA infection (44.6 percent for daptomycin vs. 48.6 percent for standard therapy, P=0.74). At the end of therapy, the success rates were 61.7 percent in the daptomycin group, as compared with 60.9 percent in the standard-therapy group (74 of 120 patients vs. 70 of 115 patients; absolute difference, 0.8 percent; 95 percent confidence interval, −11.7 to 13.3 percent). Eighty-five percent of patients treated with daptomycin and 84 percent of patients treated with standard therapy survived to the end of the study (P=0.98).Nine patients in each treatment group had a final diagnosis of left-sided endocarditis. Three patients had a successful outcome; one received daptomycin and two received standard therapy. Therapy failed in all nine patients with left-sided endocarditis caused by MRSA.
The median length of time to clearance of MRSA bacteremia (eight days and nine days, respectively; P=0.25) and MSSA bacteremia (four days and three days, respectively; P=0.28) did not differ significantly between the daptomycin and standard-therapy groups.
Reasons for Treatment Failure
The overall rates of failure of daptomycin and standard therapy were similar (55.8 percent and 58.3 percent, respectively) (Table 3Table 3
Reasons for Treatment Failure According to the Adjudication Committee.). The reasons for failure, however, were different. Failure of daptomycin treatment was more frequently attributable to persistent or relapsing S. aureus infection (19 of 120 patients [15.8 percent] vs. 11 of 115 patients [9.6 percent] in the standard-therapy group, P=0.17). In contrast, failure of standard therapy was somewhat, but not significantly more frequently, associated with treatment-limiting adverse events (occurring in 17 patients [14.8 percent] vs. 8 patients [6.7 percent] in the daptomycin group, P=0.06).Nineteen patients who were given daptomycin and 11 patients who were given standard therapy (9 were given vancomycin, and 2 were given an antistaphylococcal penicillin) had persistent or relapsing infection (P=0.17). Microbiologic failure occurred after a mean of 12 to 13 days of therapy in both groups. Among patients with microbiologic failure, more patients who were treated with daptomycin (63.2 percent) than who were treated with standard therapy (45.5 percent) had a diagnosis of complicated bacteremia. The MIC of daptomycin of the S. aureus isolates increased from baseline values in seven patients who were treated with daptomycin; six of these patients had microbiologic failure. Five of these six patients had isolates that were MRSA. In six patients with microbiologic failure, the baseline MIC was 0.25 μg of daptomycin per milliliter in five isolates and 0.5 μg per milliliter in one isolate and rose to 2 μg per milliliter in five isolates and 4 μg per milliliter in one isolate. In the central microbiology laboratory, the isolates from one of the nine patients treated with vancomycin who had microbiologic failure had an increase in the MIC of vancomycin to 2 μg per milliliter. An additional three of these nine isolates demonstrated similar rises in the MIC of vancomycin in the local microbiology laboratory only. Most patients whose treatment failed because of persistent or relapsing S. aureus infection had deep-seated infection and did not receive the necessary surgical intervention. No significant association was found between levels of plasma daptomycin or vancomycin and the occurrence of microbiologic treatment failure.
A sensitivity analysis was performed to define the relative contribution of individual reasons for failure. This analysis demonstrated similar success rates in the two groups when each reason for failure was considered, including failure of efficacy (e.g., microbiologic failure, death, or clinical failure) (Table 4Table 4
Sensitivity Analyses of Success Rates 42 Days after the End of Therapy, According to the Reported Reasons for Failure as Determined by the Adjudication Committee.). In addition, the overall success rates for daptomycin (49.2 percent) and standard therapy (48.7 percent) were similar when treatments that failed only because of treatment-limiting adverse events were classified as successes (absolute difference, 0.5 percent; 95 percent confidence interval, −12.3 to 13.3 percent) or were excluded from the analysis (data not shown).Safety and Tolerability
The overall incidence of adverse events in the two treatment groups was similar (Table 5Table 5
Results of the Safety Analysis.). Most events were considered by the investigators to be unrelated to study treatment and were mild to moderate in severity. Of the 120 patients who received daptomycin, 62 (51.7 percent) had a serious adverse event, as did 52 of 116 patients who received standard therapy (44.8 percent). Adverse events that occurred in at least 5 percent of patients in either treatment group are listed in Table 2 of the Supplementary Appendix. All differences in the rates of adverse events between groups reaching a significance level of P≤0.05 are provided in Table 3 of the Supplementary Appendix. No statistical adjustments for multiple comparisons were made.Creatine kinase elevations were significantly more common in the daptomycin group than the standard-therapy group (6.7 percent vs. 0.9 percent, P=0.04). Among patients with normal baseline levels of creatine kinase, elevations of creatine kinase were noted in 23 of 92 patients who received daptomycin, as compared with 12 of 96 patients who received standard therapy (25.0 percent vs. 12.5 percent, P=0.04). Among patients with data that could be evaluated, 2 of 111 patients who received standard therapy had elevations in creatine kinase to more than 500 IU per liter, as compared with 11 of 116 patients who received daptomycin (1.5 percent vs. 9.5 percent, P=0.02). Four of the 11 patients who received daptomycin had elevations that were greater than 10 times the upper limit of normal. Elevation of creatine kinase led to the discontinuation of treatment in 3 of 120 patients treated with daptomycin (2.5 percent). For 20 of the 24 patients who received daptomycin and who had increased levels of creatine kinase at baseline (83.3 percent), the level of creatine kinase returned to the normal range during treatment (18 patients) or after treatment (2 patients). Three patients had low-level elevations of creatine kinase (range, 114 to 451 U per liter) throughout the course of daptomycin therapy (one of whom had no follow-up data after treatment and two of whom had follow-up data approximately six weeks after treatment, with levels of creatine kinase of 215 and 389 U per liter). The fourth patient, who died on day 4, had a decrease in the creatine kinase level from 1004 U per liter on day 1 to 466 U per liter on day 4.
Eleven of 120 patients who received daptomycin had adverse events related to the peripheral nervous system (e.g., paresthesias, dysesthesias, and peripheral neuropathies) (9.2 percent), as compared with 2 of 116 patients who received standard therapy (1.7 percent, P=0.02). All of the events were classified as mild to moderate in severity; most were short-lived and resolved during continued treatment.
As compared with patients who received daptomycin, significantly more patients who received standard therapy had renal impairment as an adverse event, defined by the investigators as interstitial nephritis, toxic nephropathy, acute prerenal failure, acute or chronic renal failure, renal impairment, or renal tubular necrosis (18.1 percent vs. 6.7 percent, P=0.009) or on the basis of worsening creatinine clearance (46.8 percent vs. 19.8 percent, P<0.001). The incidence of renal impairment was similar among patients who received gentamicin and vancomycin (20.4 percent) and patients who received gentamicin and an antistaphylococcal penicillin (18.6 percent). In the safety analysis, renal impairment resulted in the discontinuation of treatment in 5 of 116 patients in the standard-therapy group (4.3 percent) and in 1 of 120 patients in the daptomycin group (0.8 percent). The proportion of patients with clinically significant decreases in renal function during treatment (a decrease in the creatinine clearance to less than 50 ml per minute or a decrease of more than 10 ml per minute from a baseline creatinine clearance of less than 50 ml per minute) was significantly higher in the standard-therapy group than in the daptomycin group by day 7 (14.2 percent vs. 5.2 percent, P=0.03) and through the end of the study (26.3 percent vs. 11.0 percent, P=0.004). Among patients who had clinically significant decreases in renal function, these decreases were reversible (defined by a final creatinine clearance within 10 ml per minute of the baseline value) in 5 of 13 patients who received daptomycin (38.5 percent) and 14 of 30 patients who received standard therapy (46.7 percent; 10 of 19 patients received an antistaphylococcal penicillin [52.6 percent], and 4 of 11 patients received vancomycin [36.4 percent]).
Discussion
Our findings demonstrate that daptomycin is not inferior to standard therapy for the treatment of S. aureus bacteremia and right-sided endocarditis caused by MSSA or MRSA. Our findings were consistent among all efficacy populations and at assessments at both the end of therapy and 42 days after the end of therapy. The study population had high rates of complicated infections, coexisting conditions, and MRSA bacteremia.3-6
The growing problem of MRSA bacteremia and endocarditis is magnified by reports of clinical failure19,20 and resistance21-24 to vancomycin. The similar success rates among patients with MRSA bacteremia and right-sided endocarditis treated with daptomycin and such patients who were treated with vancomycin suggest that daptomycin may be considered an alternative to vancomycin in the management of these serious infections.
Although elevations of creatine kinase were documented in one quarter of the patients in the daptomycin group who had normal levels of creatine kinase at baseline, only three patients withdrew from the study for this reason. In our study, clinically significant daptomycin-associated elevations of creatine kinase occurred in 6.7 percent of recipients. Patients who are taking daptomycin should be monitored for elevations in creatine kinase and skeletal-muscle dysfunction.
Patients in the standard-therapy group may have had significantly greater increases in serum creatinine because of the addition of gentamicin to the treatment regimen.25 This observation suggests that even a few days of low-dose gentamicin may result in considerable renal dysfunction in this high-risk population. Our findings provide support for the position of recent guidelines26 that the use of gentamicin in the treatment of native-valve S. aureus endocarditis should be considered optional. However, our study was not designed to examine the contribution of gentamicin to the efficacy or toxicity of standard treatment.
Nineteen of 120 patients who received daptomycin (15.8 percent) had microbiologic failure, defined as persistent or relapsing S. aureus infection. In six of these patients, S. aureus isolated during or after treatment became less susceptible to daptomycin. In contrast, 11 of 115 patients (9.6 percent) who received standard therapy had microbiologic failure, including 9 of 53 patients who received vancomycin and 2 of 62 patients who received an antistaphylococcal penicillin. In four of these nine patients who received vancomycin, the MIC of vancomycin increased to 2 μg per milliliter from baseline values of 0.5 or 1 μg per milliliter. Most patients with persistent or relapsing infection had complicated bacteremia associated with osteomyelitis or indwelling prostheses. Given the complicated nature of these infections, the contribution of decreased antimicrobial susceptibility to clinical failure is difficult to determine. However, these observations, as well as reports of clinical failures associated with reduced susceptibility to vancomycin20 and daptomycin,27 underscore the importance of adjunctive therapy, especially surgical intervention, in optimizing outcomes.
Because of the strict definition for success based on findings 42 days after the completion of therapy, treatment in many cases failed for reasons other than lack of efficacy. For example, not having blood cultures drawn at the visit 42 days after the end of therapy, despite a lack of evidence of persistent or relapsing S. aureus infection, contributed to the high failure rates seen in both groups. In addition, gentamicin therapy may have contributed to the likelihood of both microbiologic success and treatment failure associated with adverse effects in the patients who received standard therapy. However, the overall success rates 42 days after the end of therapy in both groups were similar when treatments that failed only because of treatment-limiting adverse events were classified as successes and when outcomes were assessed according to measures of efficacy (e.g., microbiologic failure, death, or clinical failure).
The open-label nature of the study might have led to bias if investigators were more likely to withdraw a patient in one of the treatment groups than in the other.28 The effect of this potential bias was minimized by including an objective microbiologic end point as part of the assessment and by the use of a blinded adjudication committee to establish the final outcome. Another limitation was the small number of patients with left-sided S. aureus endocarditis and the poor clinical outcome among these patients in both treatment groups. Additional studies are required to optimize medical and surgical therapies in the management of this life-threatening infection.
In conclusion, our results suggest that daptomycin at a dose of 6 mg per kilogram once daily is not inferior to standard therapy for the treatment of bacteremia and right-sided endocarditis caused by MSSA or MRSA.
Supported by Cubist Pharmaceuticals.
Drs. Fowler, Boucher, Corey, Abrutyn, Karchmer, Rupp, Levine, Chambers, Cabell, Link, Price, and Cosgrove report having served as consultants for Cubist Pharmaceuticals. Drs. Tally and Vigliani are employees of Cubist Pharmaceuticals. Dr. Fowler reports having received grant support from Inhibitex, Merck, Nabi, and Theravance; Dr. Corey, from Inhibitex, Merck, and Theravance; Dr. Abrutyn, from Tenet Healthcare Foundation; Dr. Karchmer, from Cubist, Merck, Theravance, and Pfizer; Dr. Rupp, from Becton Dickinson and 3M; Dr. Levine, from Cubist; Dr. Chambers, from Cubist and Ortho-McNeil; Dr. Filler, from Amgen; Dr. Zervos, from Merck and Elan; Dr. Parsonnet, from Procter & Gamble; Dr. Bernstein, from Theravance, Cubist, and Peninsula; Dr. Price, from Denver Health Medical Center, Fujisawa, GlaxoSmithKline, and Cubist; Dr. Rehm, from Cubist; Dr. Tice, from Cubist, Roche, and Merck; and Dr. Cosgrove, from Merck. Dr. Fowler reports having received lecture fees from Cubist, Nabi, and Pfizer; Dr. Boucher, from Pfizer, Schering-Plough, and Cubist; Dr. Karchmer, from Cubist; Dr. Rupp, from Aventis, Ortho-McNeil, Cubist, Schering-Plough, and Bayer; Dr. Levine, from Cubist; Dr. Chambers, from Basilea and Pfizer; Dr. Link, from Cubist; Dr. Zervos, from Pfizer, Aventis, Cubist, and Wyeth; Dr. Bernstein, from Cubist and Ortho-McNeil; Dr. Price, from Ortho-McNeil; Dr. Forrest, from AdvanDx; Dr. Rehm, from Wyeth and Cubist; and Dr. Tice, from Cubist. No other potential conflict of interest relevant to this article was reported.
Source Information
From Duke University Medical Center, Durham, N.C. (V.G.F., G.R.C., C.H.C.); Tufts New England Medical Center (H.W.B.) and Beth Israel Deaconess Medical Center (A.W.K.) — both in Boston; Drexel University College of Medicine, Philadelphia (E.A.); University of Nebraska Medical Center, Omaha (M.E.R.); Wayne State University School of Medicine, Detroit (D.P.L.); San Francisco General Hospital, San Francisco (H.F.C.); Cubist Pharmaceuticals, Lexington, Mass. (F.P.T., G.A.V.); Forsyth Medical Center, Winston-Salem, N.C. (A.S.L.); Onze Lieve Vrouw Ziekenhuis, Aalst, Belgium (I.D.); Harbor–UCLA Medical Center, Torrance, Calif. (S.G.F.); William Beaumont Hospital, Royal Oak, Mich. (M.Z.); East Carolina University, Greenville, N.C. (P.C.); Dartmouth–Hitchcock Medical Center, Lebanon, N.H. (J.P.); Veterans Affairs Medical Center, Dayton, Ohio (J.M.B.); Denver Health Medical, Denver (C.S.P.); University of Maryland School of Medicine (G.N.F.), Johns Hopkins University School of Medicine (S.E.C.) — both in Baltimore; Klinikum, University of Cologne, Cologne, Germany (G.F.); Lehigh Valley Hospital Trauma and Critical Care Research, Allentown, Pa. (M.G.); Cleveland Clinic Foundation, Cleveland (S.J.R.); Johann Wolfgang Goethe Universität, Frankfurt, Germany (H.R.B.); and University of Hawaii, and Queens Medical Center — both in Honolulu (A.T.).
Address reprint requests to Dr. Fowler at Box 3281, Division of Infectious Diseases, Duke University Medical Center, Durham, NC 27710, or at vance.fowler@duke.edu.
Appendix
In addition to the authors, the following persons participated in the S. aureus Endocarditis and Bacteremia Study: Patient Enrollment: Amarillo, Tex. — R. Akins; Atlanta — H. Albrecht; Denver — M. Barron, M. Bessesen; Fargo, N.D. — P. Carson; New York — D. Fierer; Danville, Pa. — M. Foltzer; St. Louis — D. Goodenberger; Winston-Salem, N.C. — K. High; Manhasset, N.Y. — B. Hirsch; Besançon CEDEX, France — B. Hoen; Buffalo, N.Y. — C. Hsiao; San Francisco — H. Lampiris; Philadelphia — M. Levison, B. Suh; Bethlehem, Pa. — T.P. Le; Leuven, Belgium — W. Peetermans; Chicago — D. Pitrak, J.P. Quinn, J. Segreti; Louisville, Ky. — J. Ramirez; Boston — P.A. Rice; Regensburg, Germany — B. Salzberger; Cumberland, Md. — J. Stone; Akron, Ohio — J. Tan; Rochester, Minn. — Z. Temesgen; Data and Safety Monitoring Committee: New York — K. Freeman; Charleston, S.C. — J. John, Jr.; Springfield, Mass. — D. Longworth; Cubist Pharmaceuticals Study Team: J. Alder, D. Anastasiou, R. Arbeit, J. Aziz, K. Blackerby, E. Campanaro, M. Campion, B. Eisenstein, J. Lufkin, S. Luperchio, C. Otradovec, C. Rundlett, U. Stoutenburgh, G. Thorne, P. Tipirneni.
- References
References
1
Fluit AC ,Jones ME ,Schmitz FJ ,Acar J ,Gupta R ,Verhoef J . Antimicrobial susceptibility and frequency of occurrence of clinical blood isolates in Europe from the SENTRY Antimicrobial Surveillance Program, 1997 and 1998. Clin Infect Dis 2000;30:454-460
CrossRef | Web of Science | Medline2
Wisplinghoff H ,Bischoff T ,Tallent SM ,Seifert H ,Wenzel RP ,Edmond MB . Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004;39:309-317[Erratum, Clin Infect Dis 2004;39:1093.]
CrossRef | Web of Science | Medline3
Fowler VG Jr ,Miro JM ,Hoen B , et al. Staphylococcus aureus endocarditis: a consequence of medical progress. JAMA 2005;293:3012-3021[Erratum, JAMA 2005;294: 900.]
CrossRef | Web of Science | Medline4
Miro JM ,Anguera I ,Cabell CH , et al. Staphylococcus aureus native valve infective endocarditis: report of 566 episodes from the International Collaboration on Endocarditis Merged Database. Clin Infect Dis 2005;41:507-514[Erratum, Clin Infect Dis 2005;41:1075-7.]
CrossRef | Web of Science | Medline5
Chang FY ,MacDonald BB ,Peacock JE Jr , et al. A prospective multicenter study of Staphylococcus aureus bacteremia: incidence of endocarditis, risk factors for mortality, and clinical impact of methicillin resistance. Medicine (Baltimore) 2003;82:322-332
CrossRef | Web of Science | Medline6
Fowler VG Jr ,Olsen MK ,Corey GR , et al. Clinical identifiers of complicated Staphylococcus aureus bacteremia. Arch Intern Med 2003;163:2066-2072
CrossRef | Web of Science | Medline7
Chang FY ,Peacock JE Jr ,Musher DM , et al. Staphylococcus aureus bacteremia: recurrence and the impact of antibiotic treatment in a prospective multicenter study. Medicine (Baltimore) 2003;82:333-339
CrossRef | Web of Science | Medline8
Fowler VG Jr ,Kong LK ,Corey GR , et al. Recurrent Staphylococcus aureus bacteremia: pulsed-field gel electrophoresis findings in 29 patients. J Infect Dis 1999;179:1157-1161
CrossRef | Web of Science | Medline9
Levine DP ,Fromm BS ,Reddy BR . Slow response to vancomycin or vancomycin plus rifampin in methicillin-resistant Staphylococcus aureus endocarditis. Ann Intern Med 1991;115:674-680
Web of Science | Medline10
Small PM ,Chambers HF . Vancomycin for Staphylococcus aureus endocarditis in intravenous drug users. Antimicrob Agents Chemother 1990;34:1227-1231
Web of Science | Medline11
Barry AL ,Fuchs PC ,Brown SD . In vitro activities of daptomycin against 2,789 clinical isolates from 11 North American medical centers. Antimicrob Agents Chemother 2001;45:1919-1922
CrossRef | Web of Science | Medline12
Carpenter CF ,Chambers HF . Daptomycin: another novel agent for treating infections due to drug-resistant gram-positive pathogens. Clin Infect Dis 2004;38:994-1000
CrossRef | Web of Science | Medline13
Critchley IA ,Blosser-Middleton RS ,Jones ME ,Thornsberry C ,Sahm DF ,Karlowsky JA . Baseline study to determine in vitro activities of daptomycin against gram-positive pathogens isolated in the United States in 2000-2001. Antimicrob Agents Chemother 2003;47:1689-1693
CrossRef | Web of Science | Medline14
Snydman DR ,Jacobus NV ,McDermott LA ,Lonks JR ,Boyce JM . Comparative in vitro activities of daptomycin and vancomycin against resistant gram-positive pathogens. Antimicrob Agents Chemother 2000;44:3447-3450
CrossRef | Web of Science | Medline15
Arbeit RD, Maki D, Tally FP, Campanaro E, Eisenstein BI, Daptomycin 98-01 and 99-01 Investigators
CrossRef | Web of Science | Medline16
Li JS ,Sexton DJ ,Mick N , et al. Proposed modifications to the Duke criteria for the diagnosis of infective endocarditis. Clin Infect Dis 2000;30:633-638
CrossRef | Web of Science | Medline17
Performance standards for antimicrobial testing: 15th informational supplement. CLSI/NCCLS document M100-S15. Wayne, Pa.: Clinical and Laboratory Standards Institute, 2005.
18
Cockcroft DW ,Gault MH . Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-41
CrossRef | Medline19
Fowler VG Jr ,Sakoulas G ,McIntyre LM , et al. Persistent bacteremia due to methicillin-resistant Staphylococcus aureus infection is associated with agr dysfunction and low-level in vitro resistance to thrombin-induced platelet microbicidal protein. J Infect Dis 2004;190:1140-1149
CrossRef | Web of Science | Medline20
Howden BP ,Ward PB ,Charles PG , et al. Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility. Clin Infect Dis 2004;38:521-528
CrossRef | Web of Science | Medline21
Staphylococcus aureus resistant to vancomycin -- United States, 2002. MMWR Morb Mortal Wkly Rep 2002;51:565-567
Medline22
Vancomycin-resistant Staphylococcus aureus -- Pennsylvania, 2002. MMWR Morb Mortal Wkly Rep 2002;51:902-902
Medline23
Charles PG ,Ward PB ,Johnson PD ,Howden BP ,Grayson ML . Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus. Clin Infect Dis 2004;38:448-451
CrossRef | Web of Science | Medline24
Smith TL ,Pearson ML ,Wilcox KR , et al. Emergence of vancomycin resistance in Staphylococcus aureus. N Engl J Med 1999;340:493-501
Full Text | Web of Science | Medline25
Korzeniowski O ,Sande MA . Combination antimicrobial therapy for Staphylococcus aureus endocarditis in patients addicted to parenteral drugs and in nonaddicts: a prospective study. Ann Intern Med 1982;97:496-503
Web of Science | Medline26
Baddour LM ,Wilson WR ,Bayer AS , et al. Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association -- executive summary. Circulation 2005;111:3167-3184[Erratum, Circulation 2005;112:2373.]
CrossRef | Web of Science27
Hayden MK ,Rezai K ,Hayes RA ,Lolans K ,Quinn JP ,Weinstein RA . Development of daptomycin resistance in vivo in methicillin-resistant Staphylococcus aureus. J Clin Microbiol 2005;43:5285-5287
CrossRef | Web of Science | Medline28
Rex JH ,Bennett JE ,Sugar AM , et al. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. N Engl J Med 1994;331:1325-1330
Full Text | Web of Science | Medline
- Citing Articles (308)
Citing Articles
1
S. J. van Hal, T. P. Lodise, D. L. Paterson. (2012) The Clinical Significance of Vancomycin Minimum Inhibitory Concentration in Staphylococcus aureus Infections: A Systematic Review and Meta-analysis. Clinical Infectious Diseases
CrossRef2
Franck Thuny, Dominique Grisoli, Frederic Collart, Gilbert Habib, Didier Raoult. (2012) Management of infective endocarditis: challenges and perspectives. The Lancet
CrossRef3
F. Jaureguy, M. Wolff, P. Montravers, D. Salmon, C. Cordonnier, C. Brun-Buisson, B. Fantin. (2012) Recommandations de bon usage des glycopeptides et lipoglycopeptides. Journal des Anti-infectieux
CrossRef4
Carlos Ferrera, Isidre Vilacosta, David Vivas, Carmen Olmos. (2012) Miopatía grave por daptomicina. Medicina Clínica
CrossRef5
Nuria Fernández-Hidalgo, Benito Almirante. (2012) La endocarditis infecciosa en el siglo xxi: cambios epidemiológicos, terapéuticos y pronósticos. Enfermedades Infecciosas y Microbiología Clínica
CrossRef6
R. S. Daum, B. Spellberg. (2011) Progress Toward a Staphylococcus aureus Vaccine. Clinical Infectious Diseases
CrossRef7
Steven Y. C. Tong, Luke F. Chen, Vance G. Fowler. (2011) Colonization, pathogenicity, host susceptibility, and therapeutics for Staphylococcus aureus: what is the clinical relevance?. Seminars in Immunopathology
CrossRef8
Christopher M. Bland, P. Brandon Bookstaver, Sanil Thomas. (2011) Successful re-challenge of daptomycin therapy after initial rhabdomyolysis with co-administration of simvastatin. International Journal of Antimicrobial Agents 38:6, 549-550
CrossRef9
A. M. Rivera, H. W. Boucher. (2011) Current Concepts in Antimicrobial Therapy Against Select Gram-Positive Organisms: Methicillin-Resistant Staphylococcus aureus, Penicillin-Resistant Pneumococci, and Vancomycin-Resistant Enterococci. Mayo Clinic Proceedings 86:12, 1230-1243
CrossRef10
Monton Visutthi, Potjanee Srimanote, Supayang Piyawan Voravuthikunchai. (2011) Responses in the expression of extracellular proteins in methicillin-resistant Staphylococcus aureus treated with rhodomyrtone. The Journal of Microbiology 49:6, 956-964
CrossRef11
Ian M. Gould, Michael Z. David, Silvano Esposito, Javier Garau, Gerard Lina, Teresita Mazzei, Georg Peters. (2011) New insights into meticillin-resistant Staphylococcus aureus (MRSA) pathogenesis, treatment and resistance. International Journal of Antimicrobial Agents
CrossRef12
Chung-Chih Lai, Wang-Huei Sheng, Jann-Tay Wang, Chun-Hsin Liao, Mao-Wang Ho, Chwen-Je Chen, Der-Li Chen, Ming-Uen Chou, Chien-Ming Lee, Yee-Chun Lin, Ming-Ye Pong, Shan-Chwen Chang. (2011) Safety and efficacy of daptomycin for the treatment of hospitalized adult patients in Taiwan with severe staphylococcal infections. Journal of Microbiology, Immunology and Infection
CrossRef13
C. L. Moore, P. Osaki-Kiyan, N. Z. Haque, M. B. Perri, S. Donabedian, M. J. Zervos. (2011) Daptomycin Versus Vancomycin for Bloodstream Infections Due to Methicillin-Resistant Staphylococcus aureus With a High Vancomycin Minimum Inhibitory Concentration: A Case-Control Study. Clinical Infectious Diseases
CrossRef14
E. Durante-Mangoni, R. Casillo, M. Bernardo, C. Caianiello, I. Mattucci, D. Pinto, F. Agrusta, R. Caprioli, R. Albisinni, E. Ragone, R. Utili. (2011) High-Dose Daptomycin for Cardiac Implantable Electronic Device-Related Infective Endocarditis. Clinical Infectious Diseases
CrossRef15
F. K. Gould, D. W. Denning, T. S. J. Elliott, J. Foweraker, J. D. Perry, B. D. Prendergast, J. A. T. Sandoe, M. J. Spry, R. W. Watkin. (2011) Guidelines for the diagnosis and antibiotic treatment of endocarditis in adults: a report of the Working Party of the British Society for Antimicrobial Chemotherapy. Journal of Antimicrobial Chemotherapy
CrossRef16
Mao Hagihara, Jared L Crandon, David P Nicolau. (2011) The efficacy and safety of antibiotic combination therapy for infections caused by Gram-positive and Gram-negative organisms. Expert Opinion on Drug Safety1-13
CrossRef17
Helmut Schöfer, Roswitha Bruns, Isaak Effendy, Martin Hartmann, Uta Jappe, Andreas Plettenberg, Holger Reimann, Harald Seifert, Pramod Shah, Cord Sunderkötter, Tobias Weberschock, Thomas A. Wichelhaus, Alexander Nast. (2011) Diagnosis and treatment of Staphylococcus aureus infections of the skin and mucous membranes. JDDG: Journal der Deutschen Dermatologischen Gesellschaft 9:11, 953-967
CrossRef18
Hongbin Chen, Yudong Liu, Wenjia Sun, Minjun Chen, Hui Wang. (2011) The incidence of heterogeneous vancomycin-intermediate Staphylococcus aureus correlated with increase of vancomycin MIC. Diagnostic Microbiology and Infectious Disease 71:3, 301-303
CrossRef19
EMILIE JAN, FABRICE CAMOU, JEANNETTE TEXIER-MAUGEIN, ZACHARY WHINNETT, OLIVIER CAUBET, SYLVAIN PLOUX, JEAN-LUC PELLEGRIN, PHILIPPE RITTER, PHILIPPE L. METAYER, RAYMOND ROUDAUT, MICHEL HAISSAGUERRE, PIERRE BORDACHAR. (2011) Microbiologic Characteristics and In Vitro Susceptibility to Antimicrobials in a Large Population of Patients with Cardiovascular Implantable Electronic Device Infection. Journal of Cardiovascular Electrophysiologyno-no
CrossRef20
Carlos Cervera, Ximena Castañeda, Juan M. Pericas, Ana del Río, Cristina García de la Maria, Carlos Mestres, Carlos Falces, Francesc Marco, Asuncion Moreno, Jose M. Miró. (2011) Clinical utility of daptomycin in infective endocarditis caused by Gram-positive cocci. International Journal of Antimicrobial Agents 38:5, 365-370
CrossRef21
L. M. Bush. (2011) Best Alternative to Vancomycin for Serious Methicillin-Resistant Staphylococcus aureus Infections: Let's Just Say It. Clinical Infectious Diseases 53:9, 965-966
CrossRef22
Marco Falcone, Alessandro Russo, Maria Elena Pompeo, Antonio Vena, Laura Marruncheddu, Antonio Ciccaglioni, Paolo Grossi, Carlo Mancini, Andrea Novelli, Stefania Stefani, Mario Venditti. (2011) Retrospective case–control analysis of patients with staphylococcal infections receiving daptomycin or glycopeptide therapy. International Journal of Antimicrobial Agents
CrossRef23
Kati Seidl, Arnold S. Bayer, James A. McKinnell, Steven Ellison, Scott G. Filler, Yan Q. Xiong. (2011) In vitro endothelial cell damage is positively correlated with enhanced virulence and poor vancomycin responsiveness in experimental endocarditis due to methicillin-resistant Staphylococcus aureus. Cellular Microbiology 13:10, 1530-1541
CrossRef24
Synanda Jobson, Pamela A. Moise, Romic Eskandarian. (2011) Retrospective Observational Study Comparing Vancomycin Versus Daptomycin as Initial Therapy for Staphylococcus aureus Infections. Clinical Therapeutics 33:10, 1391-1399
CrossRef25
Gary Wu, Teena Abraham, Jonathan Rapp, Fabienne Vastey, Nasser Saad, Eric Balmir. (2011) Daptomycin: evaluation of a high-dose treatment strategy. International Journal of Antimicrobial Agents 38:3, 192-196
CrossRef26
Jason William Lane, Jevon Tang, Derek Taggard, Raymond Byun. (2011) Successful Use of Daptomycin and Linezolid, Without Surgical Intervention, in the Treatment of Extensive Epidural Abscess and Bacteremia Due to Methicillin-Resistant Staphylococcus aureus (MRSA). Infectious Diseases in Clinical Practice 19:5, 362-364
CrossRef27
P. Grohs, B. Fantin, A. Lefort, M. Wolff, L. Gutmann, J.-L. Mainardi. (2011) Differences in daptomycin and vancomycin ex vivo behaviour can lead to false interpretation of negative blood cultures. Clinical Microbiology and Infection 17:8, 1264-1267
CrossRef28
Giovanni Battista Orsi, Marco Falcone, Mario Venditti. (2011) Surveillance and management of multidrug-resistant microorganisms. Expert Review of Anti-infective Therapy 9:8, 653-679
CrossRef29
Donald P. Levine. (2011) Synergy: A Cautionary Tale. Current Infectious Disease Reports 13:4, 303-304
CrossRef30
Michael D. Nailor, Jack D. Sobel. (2011) Antibiotics for Gram-Positive Bacterial Infection: Vancomycin, Teicoplanin, Quinupristin/Dalfopristin, Oxazolidinones, Daptomycin, Telavancin, and Ceftaroline. Medical Clinics of North America 95:4, 723-742
CrossRef31
Bruce A Mueller, Jason A Crompton, Brian J Donovan, Sara Yankalev, Kenneth C Lamp. (2011) Safety of Daptomycin in Patients Receiving Hemodialysis. Pharmacotherapy 31:7, 665-672
CrossRef32
R. Grubina, L. M. Baddour. (2011) 68-Year-Old Man With Persistent Methicillin-Resistant Staphylococcus aureus Bacteremia. Mayo Clinic Proceedings 86:7, e40-e43
CrossRef33
Yok-Ai Que, Philippe Moreillon. (2011) Infective endocarditis. Nature Reviews Cardiology 8:6, 322-336
CrossRef34
J.A. Capdevilla Morell, M. Mauri, M. Delgado. (2011) Fiebre en paciente portador de catéteres centrales. Revista Clínica Española 211:6, 301-306
CrossRef35
I. Das, T. Saluja, R. Steeds. (2011) Use of daptomycin in complicated cases of infective endocarditis. European Journal of Clinical Microbiology & Infectious Diseases 30:6, 807-812
CrossRef36
Ravina Kullar, Susan L Davis, Donald P Levine, Jing J Zhao, Christopher W Crank, John Segreti, George Sakoulas, Sara E Cosgrove, Michael J Rybak. (2011) High-Dose Daptomycin for Treatment of Complicated Gram-Positive Infections: A Large, Multicenter, Retrospective Study. Pharmacotherapy 31:6, 527-536
CrossRef37
Julius Larioza, Amy Girard, Richard B. Brown. (2011) Clinical Experience With Daptomycin for Outpatient Parenteral Antibiotic Therapy. The American Journal of the Medical Sciences1
CrossRef38
S. J. van Hal, D. L. Paterson, I. B. Gosbell. (2011) Emergence of daptomycin resistance following vancomycin-unresponsive Staphylococcus aureus bacteraemia in a daptomycin-naïve patient—a review of the literature. European Journal of Clinical Microbiology & Infectious Diseases 30:5, 603-610
CrossRef39
J. Kehrmann, M. Kaase, F. Szabados, S. G. Gatermann, J. Buer, P.-M. Rath, J. Steinmann. (2011) Vancomycin MIC creep in MRSA blood culture isolates from Germany: a regional problem?. European Journal of Clinical Microbiology & Infectious Diseases 30:5, 677-683
CrossRef40
K. A. Bauer, J. E. West, J.-M. Balada-Llasat, P. Pancholi, K. B. Stevenson, D. A. Goff. (2011) Reply to Parta and Musher. Clinical Infectious Diseases 52:8, 1079-1080
CrossRef41
M. Parta, D. M. Musher. (2011) Benefits and Costs of Rapid Drug Susceptibility in Staphylococcus aureus Bacteremia. Clinical Infectious Diseases 52:8, 1079-1079
CrossRef42
A. Gonzalez-Ruiz, A. Beiras-Fernandez, H. Lehmkuhl, R. A. Seaton, J. Loeffler, R. L. Chaves. (2011) Clinical experience with daptomycin in Europe: the first 2.5 years. Journal of Antimicrobial Chemotherapy 66:4, 912-919
CrossRef43
Lynn N. Fitzgibbons, Darcy L. Puls, Kimberly Mackay, Graeme N. Forrest. (2011) Management of Gram-Positive Coccal Bacteremia and Hemodialysis. American Journal of Kidney Diseases 57:4, 624-640
CrossRef44
Cybéle L. Abad, Anand Kumar, Nasia Safdar. (2011) Antimicrobial Therapy of Sepsis and Septic Shock—When Are Two Drugs Better Than One?. Critical Care Clinics 27:2, e1-e27
CrossRef45
Xingfeng Li, Cheng Jin, Wei Liu, Jian Zhou, Weijun Kong, Bing Dai, Jiabo Wang, Dan Yan, Yanling Zhao, Yun Luo, Xiaohe Xiao. (2011) A microcalorimetric method to determine antimicrobial effects of two bile acid derivatives on Staphylococcus aureus. Journal of Thermal Analysis and Calorimetry
CrossRef46
Guy E Thwaites, Jonathan D Edgeworth, Effrossyni Gkrania-Klotsas, Andrew Kirby, Robert Tilley, M Estée Török, Sarah Walker, Heiman FL Wertheim, Peter Wilson, Martin J Llewelyn. (2011) Clinical management of Staphylococcus aureus bacteraemia. The Lancet Infectious Diseases 11:3, 208-222
CrossRef47
Ian M. Gould, Roberto Cauda, Silvano Esposito, Francesco Gudiol, Teresita Mazzei, Javier Garau. (2011) Management of serious meticillin-resistant Staphylococcus aureus infections: what are the limits?. International Journal of Antimicrobial Agents 37:3, 202-209
CrossRef48
David J. Weber, William A. Rutala. (2011) Central Line–Associated Bloodstream Infections: Prevention and Management. Infectious Disease Clinics of North America 25:1, 77-102
CrossRef49
M. Carmen Fariñas, Pedro Llinares, Benito Almirante, José Barberán, Juan de Dios Colmenero, Javier Garau, Francisco Gudiol, José Hernández Quero, José Mensa, Miguel Montejo, Jerónimo Pachón, Jesús Rodríguez-Baño, Miguel Sánchez-García. (2011) New trends in infective endocarditis. Enfermedades Infecciosas y Microbiología Clínica 29, 22-35
CrossRef50
Aryan Rahbar, Marina Rabinovich, Prasad Abraham, Katherine Holloway. (2011) Case Report: Persistent Elevation in Creatine Phosphokinase Associated With High-Dose Daptomycin Therapy. Hospital Pharmacy 46:2, 117-121
CrossRef51
C. Liu, A. Bayer, S. E. Cosgrove, R. S. Daum, S. K. Fridkin, R. J. Gorwitz, S. L. Kaplan, A. W. Karchmer, D. P. Levine, B. E. Murray, M. J. Rybak, D. A. Talan, H. F. Chambers. (2011) Clinical Practice Guidelines by the Infectious Diseases Society of America for the Treatment of Methicillin-Resistant Staphylococcus aureus Infections in Adults and Children. Clinical Infectious Diseases 52:3, e18-e55
CrossRef52
Rasmus V Rasmussen, Vance G Fowler Jr, Robert Skov, Niels E Bruun. (2011) Future challenges and treatment of Staphylococcus aureus bacteremia with emphasis on MRSA. Future Microbiology 6:1, 43-56
CrossRef53
Jian-Qiao Gu, Dylan C Alexander, Jessica Rock, Paul Brian, Min Chu, Richard H Baltz. (2011) Structural characterization of a lipopeptide antibiotic A54145E(Asn3Asp9) produced by a genetically engineered strain of Streptomyces fradiae. The Journal of Antibiotics 64:1, 111-116
CrossRef54
Dylan C Alexander, Jessica Rock, Jian-Qiao Gu, Carmela Mascio, Min Chu, Paul Brian, Richard H Baltz. (2011) Production of novel lipopeptide antibiotics related to A54145 by Streptomyces fradiae mutants blocked in biosynthesis of modified amino acids and assignment of lptJ, lptK and lptL gene functions. The Journal of Antibiotics 64:1, 79-87
CrossRef55
K. Chua, F. Laurent, G. Coombs, M. L. Grayson, B. P. Howden. (2011) Not Community-Associated Methicillin-Resistant Staphylococcus aureus (CA-MRSA)! A Clinician's Guide to Community MRSA - Its Evolving Antimicrobial Resistance and Implications for Therapy. Clinical Infectious Diseases 52:1, 99-114
CrossRef56
Liang-Yu Chen, Cheng-Hsiung Huang, Shu-Chen Kuo, Chen-Yuan Hsiao, Mei-Lin Lin, Fu-Der Wang, Chang-Phone Fung. (2011) High-dose daptomycin and fosfomycin treatment of a patient with endocarditis caused by daptomycin-nonsusceptible Staphylococcus aureus: Case report. BMC Infectious Diseases 11:1, 152
CrossRef57
Kristina Nadrah, Franc Strle. (2011) Antibiotic Combinations with Daptomycin for Treatment of Staphylococcus aureus Infections. Chemotherapy Research and Practice 2011, 1-10
CrossRef58
, , , , . (2011) Clinical Guideline for the Diagnosis and Treatment of Cardiovascular Infections. Infection and Chemotherapy 43:2, 129
CrossRef59
Claudia Sola, Ricardo O Lamberghini, Marcos Ciarlantini, Ana L Egea, Patricia Gonzalez, Elda G Diaz, Vanina Huerta, Jose Gonzalez, Alejandra Corso, Mario Vilaro, Juan P Petiti, Alicia Torres, Ana Vindel, Jose L Bocco. (2011) Heterogeneous vancomycin-intermediate susceptibility in a community-associated methicillin-resistant Staphylococcus aureus epidemic clone, in a case of Infective Endocarditis in Argentina. Annals of Clinical Microbiology and Antimicrobials 10:1, 15
CrossRef60
Aron F Popov, Jan D Schmitto, Ahmad F Jebran, Christian Bireta, Martin Friedrich, Direndra Rajaruthnam, Kasim O Coskun, Anselm Braeuer, Jose Hinz, Theodor Tirilomis, Friedrich A Schoendube. (2011) Treatment of gram-positive deep sternal wound infections in cardiac surgery -experiences with daptomycin-. Journal of Cardiothoracic Surgery 6:1, 112
CrossRef61
Henry S. Fraimow, Constantine Tsigrelis. (2011) Antimicrobial Resistance in the Intensive Care Unit: Mechanisms, Epidemiology, and Management of Specific Resistant Pathogens. Critical Care Clinics 27:1, 163-205
CrossRef62
Ian M Gould. (2010) VRSA—doomsday superbug or damp squib?. The Lancet Infectious Diseases 10:12, 816-818
CrossRef63
M. Nagao, Y. Iinuma, T. Saito, Y. Matsumura, M. Shirano, A. Matsushima, S. Takakura, Y. Ito, S. Ichiyama. (2010) Close cooperation between infectious disease physicians and attending physicians can result in better management and outcome for patients with Staphylococcus aureus bacteraemia. Clinical Microbiology and Infection 16:12, 1783-1788
CrossRef64
D. Soonawala, R. A. Middelburg, M. Egger, J. P. Vandenbroucke, O. M. Dekkers. (2010) Efficacy of experimental treatments compared with standard treatments in non-inferiority trials: a meta-analysis of randomized controlled trials. International Journal of Epidemiology 39:6, 1567-1581
CrossRef65
Víctor José González Ramallo. (2010) Daptomicina en el paciente con hospitalización a domicilio. Medicina Clínica 135, 48-54
CrossRef66
Leonard Leibovici. (2010) Aminoglycoside-containing antibiotic combinations for the treatment of bacterial endocarditis: an evidence-based approach. International Journal of Antimicrobial Agents 36, S46-S49
CrossRef67
Francisco Álvarez-Lerma, María Pilar Gracia-Arnillas. (2010) Daptomicina para el tratamiento de las infecciones por microorganismos grampositivos en el paciente crítico. Medicina Clínica 135, 29-35
CrossRef68
B. Plicht, R. Erbel. (2010) Diagnostik und Therapie der Endokarditis. Herz 35:8, 542-549
CrossRef69
Francesco Scaglione. (2010) Pharmacokinetic/pharmacodynamic (PK/PD) considerations in the management of Gram-positive bacteraemia. International Journal of Antimicrobial Agents 36, S33-S39
CrossRef70
Miguel Salavert, Eva Calabuig. (2010) Papel de la daptomicina en el tratamiento de las infecciones en el paciente oncohematológico. Medicina Clínica 135, 36-47
CrossRef71
Ian M. Gould. (2010) Is vancomycin redundant for serious staphylococcal infection?. International Journal of Antimicrobial Agents 36, S55-S57
CrossRef72
Yoav Benjamini. (2010) Simultaneous and selective inference: Current successes and future challenges. Biometrical Journal 52:6, 708-721
CrossRef73
Kristine Mace Erlandson, Jose Castillo-Mancilla. (2010) The Increasing Complexity of Elderly Prescribing. Infectious Diseases in Clinical Practice 18:6, 399-401
CrossRef74
G. L. Drusano. (2010) Pharmacodynamics of ceftaroline fosamil for complicated skin and skin structure infection: rationale for improved anti-methicillin-resistant Staphylococcus aureus activity. Journal of Antimicrobial Chemotherapy 65:Supplement 4, iv33-iv39
CrossRef75
Matteo Bassetti, Elena Nicco, Francesca Ginocchio, Filippo Ansaldi, Daniela de Florentiis, Claudio Viscoli. (2010) High-dose daptomycin in documented Staphylococcus aureus infections. International Journal of Antimicrobial Agents 36:5, 459-461
CrossRef76
H.H. Sigusch, B. Zimmermann, F. Lessig, J. Thalwitzer, U.F.W. Franke. (2010) Ungewöhnliche Ursache einer Staphylococcus-aureus-Septikämie bei einem 79-jährigen Patienten. Der Internist 51:10, 1313-1317
CrossRef77
Zeina Kanafani, Helen Boucher, Vance Fowler, Christopher Cabell, Bruno Hoen, José M. Miró, Tahaniyat Lalani, Gloria Vigliani, Marilyn Campion, Ralph Corey, Donald Levine. (2010) Daptomycin compared to standard therapy for the treatment of native valve endocarditis. Enfermedades Infecciosas y Microbiología Clínica 28:8, 498-503
CrossRef78
Henrik Stender. (2010) AntibioDx. Expert Review of Molecular Diagnostics 10:7, 841-843
CrossRef79
Evangelo Boumis, Giovanni Gesu, Francesco Menichetti, Marco Ranieri, Mauro Rinaldi, Fredy Suter, Emanuele Nicastri, Francesco N. Lauria, Giampiero Carosi, Mauro Moroni, Giuseppe Ippolito. (2010) Consensus document on controversial issues in the diagnosis and treatment of bloodstream infections and endocarditis. International Journal of Infectious Diseases 14, S23-S38
CrossRef80
Richard H. Baltz, Kien T. Nguyen, Dylan C. Alexander. 2010. Reprogramming Daptomycin and A54145 Biosynthesis to Produce Novel Lipopeptide Antibiotics. , 285-308.
CrossRef81
Kevin W. McConeghy, Kerry L. LaPlante. (2010) In vitro activity of tigecycline in combination with gentamicin against biofilm-forming Staphylococcus aureus. Diagnostic Microbiology and Infectious Disease 68:1, 1-6
CrossRef82
Karen K. Kinney. (2010) Treatment of Infections Caused By Antimicrobial-Resistant Gram-Positive Bacteria. The American Journal of the Medical Sciences 340:3, 209-217
CrossRef83
Eric O. Gomez, Ahmar Jafary, Lisa L. Dever. (2010) Daptomycin and Rifampin for the Treatment of Methicillin-Resistant Staphylococcus aureus Septic Pulmonary Emboli in the Absence of Endocarditis. Microbial Drug Resistance 16:3, 241-244
CrossRef84
J. A. Crompton, D. S. North, M. Yoon, J. N. Steenbergen, K. C. Lamp, G. N. Forrest. (2010) Outcomes with daptomycin in the treatment of Staphylococcus aureus infections with a range of vancomycin MICs. Journal of Antimicrobial Chemotherapy 65:8, 1784-1791
CrossRef85
Anne-Marie Chaftari, Ray Hachem, Victor Mulanovich, Roy F. Chemaly, Javier Adachi, Kalen Jacobson, Ying Jiang, Issam Raad. (2010) Efficacy and safety of daptomycin in the treatment of Gram-positive catheter-related bloodstream infections in cancer patients. International Journal of Antimicrobial Agents 36:2, 182-186
CrossRef86
Bruce C. Friedman, Luke Mendez-Vigo, Joan Wilson, Sara Yankelev. (2010) A Retrospective Review of Clinical Experience with Daptomycin for a Variety of Wound Types in a Burn and Wound Care Facility. Southern Medical Journal 103:8, 748-752
CrossRef87
B. Al-Nawas, M. Block, G. Ertl, D. Franzen, C. Gohlke-Bärwolf, M. Herrmann, D. Horstkotte, W.V. Kern, H.-H. Kramer, A. Moritz, C.K. Naber, G. Peters, B. Plicht, G. Wahl, K. Werdan. (2010) Kommentierte Zusammenfassung der Leitlinien der European Society of Cardiology zur Infektiösen Endokarditis (Neuauflage 2009). Der Kardiologe 4:4, 285-294
CrossRef88
Richard H Baltz. (2010) Genomics and the ancient origins of the daptomycin biosynthetic gene cluster. The Journal of Antibiotics 63:8, 506-511
CrossRef89
Jesús Rodríguez-Baño, Marina de Cueto, Pilar Retamar, Juan Gálvez-Acebal. (2010) Current management of bloodstream infections. Expert Review of Anti-infective Therapy 8:7, 815-829
CrossRef90
Francisco López-Medrano, José María Aguado. (2010) Staphylococcus aureus con sensibilidad disminuida a vancomicina. Nuevos problemas para el clínico. Medicina Clínica 135:4, 160-161
CrossRef91
Hitoshi Honda, Melissa J. Krauss, Jeffrey C. Jones, Margaret A. Olsen, David K. Warren. (2010) The Value of Infectious Diseases Consultation in Staphylococcus aureus Bacteremia. The American Journal of Medicine 123:7, 631-637
CrossRef92
Natasha Atanaskova, Kenneth J. Tomecki. (2010) Innovative Management of Recurrent Furunculosis. Dermatologic Clinics 28:3, 479-487
CrossRef93
Elizabeth A. Neuner, Ed Casabar, Richard Reichley, Peggy S. McKinnon. (2010) Clinical, microbiologic, and genetic determinants of persistent methicillin-resistant Staphylococcus aureus bacteremia. Diagnostic Microbiology and Infectious Disease 67:3, 228-233
CrossRef94
Louis D. Saravolatz, Joan Pawlak, Leonard B. Johnson. (2010) In vitro activity of oritavancin against community-associated meticillin-resistant Staphylococcus aureus (CA-MRSA), vancomycin-intermediate S. aureus (VISA), vancomycin-resistant S. aureus (VRSA) and daptomycin-non-susceptible S. aureus (DNSSA). International Journal of Antimicrobial Agents 36:1, 69-72
CrossRef95
R. Canton, P. Ruiz-Garbajosa, R. L. Chaves, A. P. Johnson. (2010) A potential role for daptomycin in enterococcal infections: what is the evidence?. Journal of Antimicrobial Chemotherapy 65:6, 1126-1136
CrossRef96
José M. Entenza, Marlyse Giddey, Jacques Vouillamoz, Philippe Moreillon. (2010) In vitro prevention of the emergence of daptomycin resistance in Staphylococcus aureus and enterococci following combination with amoxicillin/clavulanic acid or ampicillin. International Journal of Antimicrobial Agents 35:5, 451-456
CrossRef97
K. Reinhart, F.M. Brunkhorst, H.-G. Bone, J. Bardutzky, C.-E. Dempfle, H. Forst, P. Gastmeier, H. Gerlach, M. Gründling, S. John, W. Kern, G. Kreymann, W. Krüger, P. Kujath, G. Marggraf, J. Martin, K. Mayer, A. Meier-Hellmann, M. Oppert, C. Putensen, M. Quintel, M. Ragaller, R. Rossaint, H. Seifert, C. Spies, F. Stüber, N. Weiler, A. Weimann, K. Werdan, T. Welte. (2010) Prävention, Diagnose, Therapie und Nachsorge der Sepsis. Intensivmedizin und Notfallmedizin 47:3, 185-207
CrossRef98
K. Reinhart, F.M. Brunkhorst, H.-G. Bone, J. Bardutzky, C.-E. Dempfle, H. Forst, P. Gastmeier, H. Gerlach, M. Gründling, S. John, W. Kern, G. Kreymann, W. Krüger, P. Kujath, G. Marggraf, J. Martin, K. Mayer, A. Meier-Hellmann, M. Oppert, C. Putensen, M. Quintel, M. Ragaller, R. Rossaint, H. Seifert, C. Spies, F. Stüber, N. Weiler, A. Weimann, K. Werdan, T. Welte. (2010) Prävention, Diagnose, Therapie und Nachsorge der Sepsis. Der Anaesthesist 59:4, 347-370
CrossRef99
Emilio V. Perez-Jorge, Steven D. Burdette, Ronald J. Markert, William B. Beam. (2010) Staphylococcus aureus bacteremia (SAB) with associated S. aureus bacteriuria (SABU) as a predictor of complications and mortality. Journal of Hospital Medicine 5:4, 208-211
CrossRef100
Christos Kosmidis, Donald P Levine. (2010) Daptomycin: pharmacology and clinical use. Expert Opinion on Pharmacotherapy 11:4, 615-625
CrossRef101
M. Dryden, A. T. Andrasevic, M. Bassetti, E. Bouza, J. Chastre, G. Cornaglia, S. Esposito, G. French, H. Giamarellou, I. C. Gyssens, D. Nathwani, S. Unal, A. Voss. (2010) A European survey of antibiotic management of methicillin-resistant Staphylococcus aureus infection: current clinical opinion and practice. Clinical Microbiology and Infection 16, 3-30
CrossRef102
Caroline B Long, Rebecca P Madan, Betsy C Herold. (2010) Diagnosis and management of community-associated MRSA infections in children. Expert Review of Anti-infective Therapy 8:2, 183-195
CrossRef103
Kathleen A. Hazlewood, Sara D. Brouse, William D. Pitcher, Ronald G. Hall. (2010) Vancomycin-Associated Nephrotoxicity: Grave Concern or Death by Character Assassination?. The American Journal of Medicine 123:2, 182.e1-182.e7
CrossRef104
Lorena Baietto, Antonio D’Avolio, Francesco Giuseppe Rosa, Silvia Garazzino, Marianna Michelazzo, Giusi Ventimiglia, Marco Siccardi, Marco Simiele, Mauro Sciandra, Giovanni Perri. (2010) Development and validation of a simultaneous extraction procedure for HPLC-MS quantification of daptomycin, amikacin, gentamicin, and rifampicin in human plasma. Analytical and Bioanalytical Chemistry 396:2, 791-798
CrossRef105
Joan F. Hilton. (2010) Noninferiority trial designs for odds ratios and risk differences. Statistics in Medicinen/a-n/a
CrossRef106
Suman M. Radhakrishna, Robert K. Rothbart, Edward McPherson. (2010) Experience with daptomycin for chronic periprosthetic joint infections. Current Orthopaedic Practice 21:1, 111-115
CrossRef107
H. M. Nguyen, C. J. Graber. (2010) Limitations of antibiotic options for invasive infections caused by methicillin-resistant Staphylococcus aureus: is combination therapy the answer?. Journal of Antimicrobial Chemotherapy 65:1, 24-36
CrossRef108
J. Segreti. (2009) Empirical therapy for serious Gram-positive infections: making the right choice. Clinical Microbiology and Infection 15, 5-10
CrossRef109
J. N. Steenbergen, J. F. Mohr, G. M. Thorne. (2009) Effects of daptomycin in combination with other antimicrobial agents: a review of in vitro and animal model studies. Journal of Antimicrobial Chemotherapy 64:6, 1130-1138
CrossRef110
Z. A. Kanafani, W. M. Kourany, V. G. Fowler, D. P. Levine, G. A. Vigliani, M. Campion, D. E. Katz, G. R. Corey, H. W. Boucher. (2009) Clinical characteristics and outcomes of diabetic patients with Staphylococcus aureus bacteremia and endocarditis. European Journal of Clinical Microbiology & Infectious Diseases 28:12, 1477-1482
CrossRef111
Gilbert Habib, Bruno Hoen, Pilar Tornos, Franck Thuny, Bernard Prendergast, Isidre Vilacosta, Philippe Moreillon, Manuel de Jesus Antunes, Ulf Thilen, John Lekakis, Maria Lengyel, Ludwig Müller, Christoph K. Naber, Petros Nihoyannopoulos, Anton Moritz, José Luis Zamorano. (2009) Guía de práctica clínica para prevención, diagnóstico y tratamiento de la endocarditis infecciosa (nueva versión 2009). Revista Española de Cardiología 62:12, 1465.e1-1465.e54
CrossRef112
J.-P. Stahl. (2009) Maximizing positive outcomes for patients with staphylococcal infections. Clinical Microbiology and Infection 15, 26-32
CrossRef113
Michael D. Nailor, Jack D. Sobel. (2009) Antibiotics for Gram-Positive Bacterial Infections: Vancomycin, Teicoplanin, Quinupristin/Dalfopristin, Oxazolidinones, Daptomycin, Dalbavancin, and Telavancin. Infectious Disease Clinics of North America 23:4, 965-982
CrossRef114
E. Bouza. (2009) New therapeutic choices for infections caused by methicillin-resistant Staphylococcus aureus. Clinical Microbiology and Infection 15, 44-52
CrossRef115
J. M. Mir
. (2009) Optimizing outcomes in patients with serious Gram-positive infections. Clinical Microbiology and Infection 15, 1-3
CrossRef116
G. Sakoulas. (2009) Clinical outcomes with daptomycin: a post-marketing, real-world evaluation. Clinical Microbiology and Infection 15, 11-16
CrossRef117
Dennis A. K. Rice, Luke Mendez-Vigo. (2009) Daptomycin in bone and joint infections: a review of the literature. Archives of Orthopaedic and Trauma Surgery 129:11, 1495-1504
CrossRef118
Knut Ohlsen. (2009) Novel antibiotics for the treatment of Staphylococcus aureus. Expert Review of Clinical Pharmacology 2:6, 661-672
CrossRef119
, , G. Habib, B. Hoen, P. Tornos, F. Thuny, B. Prendergast, I. Vilacosta, P. Moreillon, M. de Jesus Antunes, U. Thilen, J. Lekakis, M. Lengyel, L. Muller, C. K. Naber, P. Nihoyannopoulos, A. Moritz, J. L. Zamorano, , A. Vahanian, A. Auricchio, J. Bax, C. Ceconi, V. Dean, G. Filippatos, C. Funck-Brentano, R. Hobbs, P. Kearney, T. McDonagh, K. McGregor, B. A. Popescu, Z. Reiner, U. Sechtem, P. A. Sirnes, M. Tendera, P. Vardas, P. Widimsky, , A. Vahanian, R. Aguilar, M. G. Bongiorni, M. Borger, E. Butchart, N. Danchin, F. Delahaye, R. Erbel, D. Franzen, K. Gould, R. Hall, C. Hassager, K. Kjeldsen, R. McManus, J. M. Miro, A. Mokracek, R. Rosenhek, J. A. San Roman Calvar, P. Seferovic, C. Selton-Suty, M. S. Uva, R. Trinchero, G. van Camp. (2009) Guidelines on the prevention, diagnosis, and treatment of infective endocarditis (new version 2009): The Task Force on the Prevention, Diagnosis, and Treatment of Infective Endocarditis of the European Society of Cardiology (ESC). European Heart Journal 30:19, 2369-2413
CrossRef120
Eric V. Granowitz, Richard B. Brown. 2009. Adverse Reactions to Antibiotics inCriticalCare. , 542-556.
CrossRef121
Pamela A Moise, Donald North, Judith N Steenbergen, George Sakoulas. (2009) Susceptibility relationship between vancomycin and daptomycin in Staphylococcus aureus: facts and assumptions. The Lancet Infectious Diseases 9:10, 617-624
CrossRef122
Martin E Stryjewski, G Ralph Corey. (2009) New treatments for methicillin-resistant Staphylococcus aureus. Current Opinion in Critical Care 15:5, 403-412
CrossRef123
Robert C. Owens. (2009) Antimicrobial Stewardship: Application in the Intensive Care Unit. Infectious Disease Clinics of North America 23:3, 683-702
CrossRef124
Matteo Bassetti, Małgorzata Mikulska, Eva Schenone, Laura Nicolini, Claudio Viscoli. (2009) Long course of daptomycin in the treatment of meticillin-resistant Staphylococcus epidermidis endocarditis and spondylodiscitis. International Journal of Antimicrobial Agents 34:3, 290-291
CrossRef125
Curtis D. Collins, Brian D. DeSmet, Daryl D. DePestel. (2009) Institutional Experience With Daptomycin Treatment in Patients With Gram-Positive Infections. Hospital Pharmacy 44:9, 766-775
CrossRef126
Kenneth V. I. Rolston. (2009) New antimicrobial agents for the treatment of bacterial infections in cancer patients. Hematological Oncology 27:3, 107-114
CrossRef127
George M. Eliopoulos. (2009) Microbiology of drugs for treating multiply drug-resistant Gram-positive bacteria. Journal of Infection 59, S17-S24
CrossRef128
D. M. Livermore. (2009) Has the era of untreatable infections arrived?. Journal of Antimicrobial Chemotherapy 64:Supplement 1, i29-i36
CrossRef129
Henry F. Chambers, Frank R. DeLeo. (2009) Waves of resistance: Staphylococcus aureus in the antibiotic era. Nature Reviews Microbiology 7:9, 629-641
CrossRef130
Kenneth V. I. Rolston. (2009) The Use of New and Better Antibiotics for Bacterial Infections in Patients With Leukemia. Clinical Lymphoma, Myeloma & Leukemia 9:0, S357-S363
CrossRef131
George Sakoulas, Jack Brown, Kenneth C. Lamp, Lawrence V. Friedrich, Kimberly C. Lindfield. (2009) Clinical outcomes of patients receiving daptomycin for the treatment of Staphylococcus aureus infections and assessment of clinical factors for daptomycin failure: A retrospective cohort study utilizing the Cubicin® Outcomes Registry and Experience. Clinical Therapeutics 31:9, 1936-1945
CrossRef132
D. Nathwani. (2009) Developments in outpatient parenteral antimicrobial therapy (OPAT) for Gram-positive infections in Europe, and the potential impact of daptomycin. Journal of Antimicrobial Chemotherapy 64:3, 447-453
CrossRef133
Juan J. Picazo, Carmen Betriu, Esther Culebras, Iciar Rodríguez-Avial, María Gómez, Fátima López. (2009) Activity of daptomycin against staphylococci collected from bloodstream infections in Spanish medical centers. Diagnostic Microbiology and Infectious Disease 64:4, 448-451
CrossRef134
Evelina Tacconelli. (2009) Antimicrobial use: risk driver of multidrug resistant microorganisms in healthcare settings. Current Opinion in Infectious Diseases 22:4, 352-358
CrossRef135
Ian M. Gould. (2009) Antibiotics, skin and soft tissue infection and meticillin-resistant Staphylococcus aureus: cause and effect. International Journal of Antimicrobial Agents 34, S8-S11
CrossRef136
Jason C Gallagher, Mirza E Perez, Elizabeth A Marino, Laura G LoCastro, Lauren A Abrardo, Conan MacDougall. (2009) Daptomycin Therapy for Vancomycin-Resistant Enterococcal Bacteremia: A Retrospective Case Series of 30 Patients. Pharmacotherapy 29:7, 792-799
CrossRef137
Pavani Reddy, Smitha Chadaga, Gary A. Noskin. (2009) Antibiotic considerations in the treatment of multidrug-resistant (MDR) pathogens: A case-based review. Journal of Hospital Medicine 4:6, E8-E15
CrossRef138
A. Chakraborty, S. Roy, J. Loeffler, R. L. Chaves. (2009) Comparison of the pharmacokinetics, safety and tolerability of daptomycin in healthy adult volunteers following intravenous administration by 30 min infusion or 2 min injection. Journal of Antimicrobial Chemotherapy 64:1, 151-158
CrossRef139
V. Mave, J. Garcia-Diaz, T. Islam, R. Hasbun. (2009) Vancomycin-resistant enterococcal bacteraemia: is daptomycin as effective as linezolid?. Journal of Antimicrobial Chemotherapy 64:1, 175-180
CrossRef140
Spyros Pournaras, Elias Iosifidis, Emmanuel Roilides. (2009) Advances in Antibacterial Therapy Against Emerging Bacterial Pathogens. Seminars in Hematology 46:3, 198-211
CrossRef141
R. O. Odero, K. O. Cleveland, M. S. Gelfand. (2009) Rhabdomyolysis and acute renal failure associated with the co-administration of daptomycin and an HMG-CoA reductase inhibitor. Journal of Antimicrobial Chemotherapy 63:6, 1299-1300
CrossRef142
Fred C. Tenover, Scott W. Sinner, Robert E. Segal, Vanthida Huang, Shandline S. Alexandre, John E. McGowan, Melvin P. Weinstein. (2009) Characterisation of a Staphylococcus aureus strain with progressive loss of susceptibility to vancomycin and daptomycin during therapy. International Journal of Antimicrobial Agents 33:6, 564-568
CrossRef143
Lara M. Jacobson, Aaron M. Milstone, Jonathan Zenilman, Karen C. Carroll, Ravit Arav-Boger. (2009) DAPTOMYCIN THERAPY FAILURE IN AN ADOLESCENT WITH METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS BACTEREMIA. The Pediatric Infectious Disease Journal 28:5, 445-447
CrossRef144
K. Philip, W.Y. Teoh, S. Muniandy, H. Yaakob. (2009) Pathogenic Bacteria Predominate in the Oral Cavity of Malaysian Subjects. Journal of Biological Sciences 9:5, 438-444
CrossRef145
Amy M. Creel, Spencer H. Durham, Kim W. Benner, Jeffrey A. Alten, Margaret K. Winkler. (2009) Severe invasive community-associated methicillin-resistant Staphylococcus aureus infections in previously healthy children *. Pediatric Critical Care Medicine 10:3, 323-327
CrossRef146
Pedro M. Olaechea. (2009) Infecciones bacterianas en el paciente crítico: revisión de los estudios publicados entre 2006 y 2008. Medicina Intensiva 33:4, 196-206
CrossRef147
Carlos Pigrau, Benito Almirante. (2009) Oxazolidinonas, glucopéptidos y lipopéptidos cíclicos. Enfermedades Infecciosas y Microbiología Clínica 27:4, 236-246
CrossRef148
Richard H Baltz. (2009) Daptomycin: mechanisms of action and resistance, and biosynthetic engineering. Current Opinion in Chemical Biology 13:2, 144-151
CrossRef149
P. A. Moise, D. S. Smyth, D. A. Robinson, N. El-Fawal, C. McCalla, G. Sakoulas. (2009) Genotypic and phenotypic relationships among methicillin-resistant Staphylococcus aureus from three multicentre bacteraemia studies. Journal of Antimicrobial Chemotherapy 63:5, 873-876
CrossRef150
F. K. Gould, R. Brindle, P. R. Chadwick, A. P. Fraise, S. Hill, D. Nathwani, G. L. Ridgway, M. J. Spry, R. E. Warren, . (2009) Guidelines (2008) for the prophylaxis and treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections in the United Kingdom. Journal of Antimicrobial Chemotherapy 63:5, 849-861
CrossRef151
S. Rehm, M. Campion, D. E. Katz, R. Russo, H. W. Boucher. (2009) Community-based outpatient parenteral antimicrobial therapy (CoPAT) for Staphylococcus aureus bacteraemia with or without infective endocarditis: analysis of the randomized trial comparing daptomycin with standard therapy. Journal of Antimicrobial Chemotherapy 63:5, 1034-1042
CrossRef152
R. Leclercq. (2009) Epidemiological and resistance issues in multidrug-resistant staphylococci and enterococci. Clinical Microbiology and Infection 15:3, 224-231
CrossRef153
Howard S. Gold, Satish K. Pillai. (2009) Antistaphylococcal Agents. Infectious Disease Clinics of North America 23:1, 99-131
CrossRef154
P. E. Pertel, B. I. Eisenstein, A. S. Link, B. Donfrid, E. J. A. Biermann, P. Bernardo, W. J. Martone. (2009) The efficacy and safety of daptomycin vs. vancomycin for the treatment of cellulitis and erysipelas. International Journal of Clinical Practice 63:3, 368-375
CrossRef155
Martha I Buitrago, Jason A Crompton, Shellie Bertolami, Donald S North, Richard A Nathan. (2009) Extremely Low Excretion of Daptomycin into Breast Milk of a Nursing Mother with Methicillin-Resistant Staphylococcus aureus Pelvic Inflammatory Disease. Pharmacotherapy 29:3, 347-351
CrossRef156
Helio S. Sader, Thomas R. Fritsche, Ronald N. Jones. (2009) Antimicrobial activity of daptomycin and selected comparators tested against bloodstream Staphylococcus aureus isolates from hemodialysis patients. International Journal of Infectious Diseases 13:2, 291-295
CrossRef157
Rupali K. Doshi, Gopi Patel, Richard MacKay, Frances Wallach. (2009) Healthcare-associated Infections: Epidemiology, Prevention, and Therapy. Mount Sinai Journal of Medicine: A Journal of Translational and Personalized Medicine 76:1, 84-94
CrossRef158
Francisco Gudiol, José María Aguado, Álvaro Pascual, Miquel Pujol, Benito Almirante, José María Miró, Emilia Cercenado, María de los Ángeles Domínguez, Álex Soriano, Jesús Rodríguez-Baño, Jordi Vallés, Mercedes Palomar, Pilar Tornos, Emilio Bouza. (2009) Documento de consenso sobre el tratamiento de la bacteriemia y la endocarditis causada por Staphylococcus aureus resistente a la meticilina. Enfermedades Infecciosas y Microbiología Clínica 27:2, 105-115
CrossRef159
J. Garau, E. Bouza, J. Chastre, F. Gudiol, S. Harbarth. (2009) Management of methicillin-resistant Staphylococcus aureus infections. Clinical Microbiology and Infection 15:2, 125-136
CrossRef160
Paolo A. Grossi. (2009) Early appropriate therapy of Gram-positive bloodstream infections: the conservative use of new drugs. International Journal of Antimicrobial Agents 34, S31-S34
CrossRef161
Elizabeth D. Hermsen, Sara S. Shull, Isaac F. Mitropoulos, Susan E. Puumala, Mark E. Rupp. (2009) Prospective Evaluation of Clinical and Economic Outcomes Associated With Treatment of Serious Infections Due to Gram-Positive Cocci. Infectious Diseases in Clinical Practice 17:1, 17-21
CrossRef162
Carlos Cervera, Manel Almela, José A. Martínez-Martínez, Asunción Moreno, José M. Miró. (2009) Risk factors and management of Gram-positive bacteraemia. International Journal of Antimicrobial Agents 34, S26-S30
CrossRef163
Yoav Keynan, Ethan Rubinstein. (2009) Are drug clinical trials broadly applicable? The case of staphylococcal bacteraemia. International Journal of Antimicrobial Agents 34, S35-S37
CrossRef164
Kristine Buchholtz, Carsten T. Larsen, Christian Hassager, Niels E. Bruun. (2009) Severity of Gentamicin's Nephrotoxic Effect on Patients with Infective Endocarditis: A Prospective Observational Cohort Study of 373 Patients. Clinical Infectious Diseases 48:1, 65-71
CrossRef165
Stan Deresinski. (2009) Antibiotic therapy of vascular catheter-related bloodstream infections: is vancomycin the optimal choice for Staphylococcus aureus infections?. International Journal of Antimicrobial Agents 34, S43-S46
CrossRef166
G. Ralph Corey, Martin E. Stryjewski, Richard J. Everts. (2009) Short-course therapy for bloodstream infections in immunocompetent adults. International Journal of Antimicrobial Agents 34, S47-S51
CrossRef167
Drosos E. Karageorgopoulos, Matthew E. Falagas. (2009) New antibiotics: optimal use in current clinical practice. International Journal of Antimicrobial Agents 34, S55-S62
CrossRef168
Mukesh Patel. (2009) Community-Associated Meticillin-Resistant Staphylococcus aureus Infections. Drugs 69:6, 693-716
CrossRef169
K. Banwan, A.C. Senok, V.O. Rotimi. (2009) Antibiotic therapeutic options for infections caused by drug-resistant Gram-positive cocci. Journal of Infection and Public Health 2:2, 62-73
CrossRef170
Anuradha Ganesan. (2008) Methicillin-Resistant Staphylococcus aureus Bacteremia and Pneumonia. Disease-a-Month 54:12, 787-792
CrossRef171
Helen W. Boucher. (2008) Is It Possible to Blind a Trial for Community‐Acquired Pneumonia?. Clinical Infectious Diseases 47:S3, S210-S215
CrossRef172
Mark D. Johnson, Catherine F. Decker. (2008) Antimicrobial Agents in Treatment of MRSA Infections. Disease-a-Month 54:12, 793-800
CrossRef173
Chia-Ying Liu, Jiun-Ling Wang, Yu-Tsung Huang, Po-Ren Hsueh. (2008) Development of multiple lung abscesses during daptomycin treatment for right-sided endocarditis caused by meticillin-resistant Staphylococcus aureus. International Journal of Antimicrobial Agents 32:6, 544-545
CrossRef174
Jae-Hoon Song. (2008) What's new on the antimicrobial horizon?. International Journal of Antimicrobial Agents 32, S207-S213
CrossRef175
Benito Almirante, José M. Miró. (2008) Infecciones asociadas a las válvulas protésicas cardíacas, las prótesis vasculares y los dispositivos de electroestimulación cardíacos. Enfermedades Infecciosas y Microbiología Clínica 26:10, 647-664
CrossRef176
P. M. Hawkey. (2008) Pre-clinical experience with daptomycin. Journal of Antimicrobial Chemotherapy 62:Supplement 3, iii7-iii14
CrossRef177
R. Hope, D. M. Livermore, G. Brick, M. Lillie, R. Reynolds, . (2008) Non-susceptibility trends among staphylococci from bacteraemias in the UK and Ireland, 2001-06. Journal of Antimicrobial Chemotherapy 62:Supplement 2, ii65-ii74
CrossRef178
R. E. Warren. (2008) Daptomycin in endocarditis and bacteraemia: a British perspective. Journal of Antimicrobial Chemotherapy 62:Supplement 3, iii25-iii33
CrossRef179
R. A. Seaton. (2008) Daptomycin: rationale and role in the management of skin and soft tissue infections. Journal of Antimicrobial Chemotherapy 62:Supplement 3, iii15-iii23
CrossRef180
Adriana Manzur, Fe Tubau, Cristina Suárez, Miquel Pujol. (2008) Bacteriemia persistente por Staphylococcus aureus resistente a meticilina. Enfermedades Infecciosas y Microbiología Clínica 26:9, 593-594
CrossRef181
Paschalis I. Vergidis, Matthew E. Falagas. (2008) New antibiotic agents for bloodstream infections. International Journal of Antimicrobial Agents 32, S60-S65
CrossRef182
Raphael Saginur, Kathryn N. Suh. (2008) Staphylococcus aureus bacteraemia of unknown primary source: Where do we stand?. International Journal of Antimicrobial Agents 32, S21-S25
CrossRef183
D. P. Levine. (2008) Clinical experience with daptomycin: bacteraemia and endocarditis. Journal of Antimicrobial Chemotherapy 62:Supplement 3, iii35-iii39
CrossRef184
D. M. Livermore. (2008) Future directions with daptomycin. Journal of Antimicrobial Chemotherapy 62:Supplement 3, iii41-iii49
CrossRef185
Yaqoob Bhat, Abhijit M. Bal, Stuart Rochow, Ian M. Gould. (2008) An unusual case of Corynebacterium striatum endocarditis and a review of the literature. International Journal of Infectious Diseases 12:6, 672-674
CrossRef186
S. N. Leonard, M. J. Rybak. (2008) Evaluation of vancomycin and daptomycin against methicillin-resistant Staphylococcus aureus and heterogeneously vancomycin-intermediate S. aureus in an in vitro pharmacokinetic/pharmacodynamic model with simulated endocardial vegetations. Journal of Antimicrobial Chemotherapy 63:1, 155-160
CrossRef187
Adam L. Cohen, David Calfee, Scott K. Fridkin, Susan S. Huang, John A. Jernigan, Ebbing Lautenbach, Shannon Oriola, Keith M. Ramsey, Cassandra D. Salgado, Robert A. Weinstein, . (2008) Recommendations for Metrics for Multidrug‐Resistant Organisms in Healthcare Settings: SHEA/HICPAC Position Paper • . Infection Control and Hospital Epidemiology 29:10, 901-913
CrossRef188
Elena Loza, María Isabel Morosini, Álvaro Pascual, Fe Tubau, Juan Alcalá, Josefina Liñares, José Ramón Hernández-Bello, Fernando Baquero, Evelio Perea, Rogelio Martín, Ronald N. Jones, Rafael Cantón. (2008) Actividad comparativa de daptomicina frente a microorganismos grampositivos: programa SENTRY España (2002-2006). Enfermedades Infecciosas y Microbiología Clínica 26:8, 489-494
CrossRef189
Luis Fernando Aranha Camargo. (2008) TREATMENT OF SEVERE INFECTIONS CAUSED BY STAPHYLOCOCCUS AUREUS. Shock 30:Suppl 1, 67-69
CrossRef190
B. Plicht, C.K. Naber, R. Erbel. (2008) Therapie und Prophylaxe der infektiösen Endokarditis. Der Internist 49:10, 1219-1230
CrossRef191
J.A. Capdevila Morell. (2008) Uso empírico de antibióticos en infecciones nosocomiales. Revista Clínica Española 208:9, 423-425
CrossRef192
Natasha VDV Ratnaraja, Peter M Hawkey. (2008) Current challenges in treating MRSA: what are the options?. Expert Review of Anti-infective Therapy 6:5, 601-618
CrossRef193
Marin H. Kollef. (2008) Broad‐Spectrum Antimicrobials and the Treatment of Serious Bacterial Infections: Getting It Right Up Front. Clinical Infectious Diseases 47:S1, S3-S13
CrossRef194
S. J. Rehm, H. Boucher, D. Levine, M. Campion, B. I. Eisenstein, G. A. Vigliani, G.R. Corey, E. Abrutyn. (2008) Daptomycin versus vancomycin plus gentamicin for treatment of bacteraemia and endocarditis due to Staphylococcus aureus: subset analysis of patients infected with methicillin-resistant isolates. Journal of Antimicrobial Chemotherapy 62:6, 1413-1421
CrossRef195
G. Jacobsson, E. Gustafsson, R. Andersson. (2008) Outcome for invasive Staphylococcus aureus infections. European Journal of Clinical Microbiology & Infectious Diseases 27:9, 839-848
CrossRef196
G. Fritsche, G. Weiss. (2008) Therapeutic options for the treatment of infections with multiresistant grampositive bacteria in oncological patients. memo - Magazine of European Medical Oncology 1:3, 177-180
CrossRef197
D. E. Katz, K. C. Lindfield, J. N. Steenbergen, D. P. Benziger, K. J. Blackerby, A. G. Knapp, W. J. Martone. (2008) A pilot study of high-dose short duration daptomycin for the treatment of patients with complicated skin and skin structure infections caused by gram-positive bacteria. International Journal of Clinical Practice 62:9, 1455-1464
CrossRef198
Kyle J. Popovich, Bala Hota, Robert A. Weinstein. (2008) Treatment of community-associated methicillin-resistant Staphylococcus aureus. Current Infectious Disease Reports 10:5, 411-420
CrossRef199
S. Doekel, M.-F. Coeffet-Le Gal, J.-Q. Gu, M. Chu, R. H. Baltz, P. Brian. (2008) Non-ribosomal peptide synthetase module fusions to produce derivatives of daptomycin in Streptomyces roseosporus. Microbiology 154:9, 2872-2880
CrossRef200
Esteban C Nannini, Martin E Stryjewski. (2008) A new lipoglycopeptide: telavancin. Expert Opinion on Pharmacotherapy 9:12, 2197-2207
CrossRef201
W. J. Martone, K. C. Lindfield, D. E. Katz. (2008) Outpatient parenteral antibiotic therapy with daptomycin: insights from a patient registry. International Journal of Clinical Practice 62:8, 1183-1187
CrossRef202
Julia C. Dombrowski, Lisa G. Winston. (2008) Clinical failures of appropriately-treated methicillin-resistant Staphylococcus aureus infections. Journal of Infection 57:2, 110-115
CrossRef203
Jason A. Roberts, Peter Kruger, David L. Paterson, Jeffrey Lipman. (2008) Antibiotic resistance—What’s dosing got to do with it?. Critical Care Medicine 36:8, 2433-2440
CrossRef204
J.A. Capdevila Morell. (2008) Uso empírico de antibióticos en infecciones nosocomiales. Revista Clínica Española 208:7, 323-325
CrossRef205
George Sakoulas, Robert C. Moellering, Jr.. (2008) Increasing Antibiotic Resistance among Methicillin‐Resistant Staphylococcus aureus Strains. Clinical Infectious Diseases 46:S5, S360-S367
CrossRef206
Sara E. Cosgrove, Vance G. Fowler, Jr.. (2008) Management of Methicillin‐Resistant Staphylococcus aureus Bacteremia. Clinical Infectious Diseases 46:S5, S386-S393
CrossRef207
M. Sharma, K. Riederer, P. Chase, R. Khatib. (2008) High rate of decreasing daptomycin susceptibility during the treatment of persistent Staphylococcus aureus bacteremia. European Journal of Clinical Microbiology & Infectious Diseases 27:6, 433-437
CrossRef208
Ronald G. Hall, Kenna D. Payne, Amy M. Bain, Anita P. Rahman, Sean T. Nguyen, Susan A. Eaton, Anthony J. Busti, Stephen L. Vu, Roger Bedimo. (2008) Multicenter Evaluation of Vancomycin Dosing: Emphasis on Obesity. The American Journal of Medicine 121:6, 515-518
CrossRef209
Edina Avdic, Sara E Cosgrove. (2008) Management and control strategies for community-associated methicillin-resistant Staphylococcus aureus. Expert Opinion on Pharmacotherapy 9:9, 1463-1479
CrossRef210
Floriana Campanile, Dafne Bongiorno, Sonia Borbone, Marco Falcone, Maddalena Giannella, Mario Venditti, Stefania Stefani. (2008) In vitro activity of daptomycin against methicillin- and multi-resistant Staphylococcus haemolyticus invasive isolates carrying different mec complexes. Diagnostic Microbiology and Infectious Disease 61:2, 227-231
CrossRef211
D. Y. Aksoy, S. Unal. (2008) New antimicrobial agents for the treatment of Gram-positive bacterial infections. Clinical Microbiology and Infection 14:5, 411-420
CrossRef212
R.A. Seaton, A.A. MacConnachie. (2008) Experience with daptomycin in an infectious diseases service over 1 year: utility in an outpatient parenteral antibiotic programme. International Journal of Antimicrobial Agents 31:5, 492-497
CrossRef213
Robert C. Owens. (2008) Antimicrobial stewardship: concepts and strategies in the 21st century. Diagnostic Microbiology and Infectious Disease 61:1, 110-128
CrossRef214
Kyle J. Popovich, Bala Hota. (2008) Treatment and prevention of community-associated methicillin-resistant Staphylococcus aureus skin and soft tissue infections. Dermatologic Therapy 21:3, 167-179
CrossRef215
John H. Powers. (2008) Editorial Commentary: Reassessing the Design, Conduct, and Analysis of Clinical Trials of Therapy for Community‐Acquired Pneumonia. Clinical Infectious Diseases 46:8, 1152-1156
CrossRef216
Susan M. Abdel-Rahman, David P. Benziger, Richard F. Jacobs, Hasan S. Jafri, Erica Fischer Hong, Gregory L. Kearns. (2008) Single-Dose Pharmacokinetics of Daptomycin in Children With Suspected or Proved Gram-Positive Infections. The Pediatric Infectious Disease Journal 27:4, 330-334
CrossRef217
Timothy C. Jenkins, Connie S. Price, Allison L. Sabel, Philip S. Mehler, William J. Burman. (2008) Impact of Routine Infectious Diseases Service Consultation on the Evaluation, Management, and Outcomes of Staphylococcus aureus Bacteremia. Clinical Infectious Diseases 46:7, 1000-1008
CrossRef218
Paul B Cornia, Heather L Davidson, Benjamin A Lipsky. (2008) The evaluation and treatment of complicated skin and skin structure infections. Expert Opinion on Pharmacotherapy 9:5, 717-730
CrossRef219
Y. Carmeli. (2008) Strategies for managing today’s infections. Clinical Microbiology and Infection 14:s3, 22-31
CrossRef220
Ian M. Gould. (2008) Clinical relevance of increasing glycopeptide MICs against Staphylococcus aureus. International Journal of Antimicrobial Agents 31, 1-9
CrossRef221
A. Makinson, V. Le Moing. (2008) Nouveaux antibiotiques anti-gram+dans l’endocardite infectieuse, une place encore difficile à préciser. Annales de Cardiologie et d'Angéiologie 57:2, 88-92
CrossRef222
Robert C. Moellering, Jr.. (2008) Current Treatment Options for Community‐Acquired Methicillin‐Resistant Staphylococcus aureus Infection. Clinical Infectious Diseases 46:7, 1032-1037
CrossRef223
Emilio Bouza, Almudena Burillo, Patricia Munoz. (2008) Empiric Therapy for Intravenous Central Line Infections and Nosocomially-Acquired Acute Bacterial Endocarditis. Critical Care Clinics 24:2, 293-312
CrossRef224
Jeffrey Alder. (2008) The Use of Daptomycin for Staphylococcus Aureus Infections in Critical Care Medicine. Critical Care Clinics 24:2, 349-363
CrossRef225
Frank P. Tverdek, Christopher W. Crank, John Segreti. (2008) Antibiotic Therapy of Methicillin-Resistant Staphylococcus Aureus in Critical Care. Critical Care Clinics 24:2, 249-260
CrossRef226
David A. Talan, Gregory J. Moran, Fredrick M. Abrahamian. (2008) Severe Sepsis and Septic Shock in the Emergency Department. Infectious Disease Clinics of North America 22:1, 1-31
CrossRef227
C. K. Naber. (2008) Future strategies for treating Staphylococcus aureus bloodstream infections. Clinical Microbiology and Infection 14, 26-34
CrossRef228
B. I. Eisenstein. (2008) Treatment of staphylococcal infections with cyclic lipopeptides. Clinical Microbiology and Infection 14, 10-16
CrossRef229
Louis B. Rice, John G. Bartlett, Donald E. Craven, Dennis L. Stevens, Robert C. Moellering, George M. Eliopoulos. (2008) Emerging Treatments for Resistant Bacterial Infections and Pathogen-Focused Therapy. Infectious Diseases in Clinical Practice 16:Suppl. 1, S1-S20
CrossRef230
Françoise Van Bambeke, Marie-Paule Mingeot-Leclercq, Marc J. Struelens, Paul M. Tulkens. (2008) The bacterial envelope as a target for novel anti-MRSA antibiotics. Trends in Pharmacological Sciences 29:3, 124-134
CrossRef231
Donald P. Levine. (2008) Vancomycin: Understanding Its Past and Preserving Its Future. Southern Medical Journal 101:3, 284-291
CrossRef232
W. Graninger. (2008) Serious staphylococcal infections-cyclic lipopeptides: meeting new challenges. Clinical Microbiology and Infection 14, 1-2
CrossRef233
Y.-T. Huang, C.-H. Liao, L.-J. Teng, P.-R. Hsueh. (2008) Comparative bactericidal activities of daptomycin, glycopeptides, linezolid and tigecycline against blood isolates of Gram-positive bacteria in Taiwan. Clinical Microbiology and Infection 14:2, 124-129
CrossRef234
A. Simon Lynch, Gregory T. Robertson. (2008) Bacterial and Fungal Biofilm Infections. Annual Review of Medicine 59:1, 415-428
CrossRef235
James S Lewis, Michael W Ellis. (2008) Approaches to serious methicillin-resistant Staphylococcus aureus infections with decreased susceptibility to vancomycin: clinical significance and options for management. Current Opinion in Internal Medicine 7:1, 65-70
CrossRef236
Garyphallia Poulakou, Helen Giamarellou. (2008) Oritavancin: a new promising agent in the treatment of infections due to Gram-positive pathogens. Expert Opinion on Investigational Drugs 17:2, 225-243
CrossRef237
Ulrike Traut, Lukas Br
CrossRef238
A. Soriano, F. Marco, J. A. Martinez, E. Pisos, M. Almela, V. P. Dimova, D. Alamo, M. Ortega, J. Lopez, J. Mensa. (2008) Influence of Vancomycin Minimum Inhibitory Concentration on the Treatment of Methicillin-Resistant Staphylococcus aureus Bacteremia. Clinical Infectious Diseases 46:2, 193-200
CrossRef239
Benito Almirante. (2008) Bacteriemia e infecciones endovasculares por grampositivos: nuevas opciones terapéuticas. Enfermedades Infecciosas y Microbiología Clínica 26, 44-52
CrossRef240
Jason G Newland, Gregory L Kearns. (2008) Treatment Strategies for Methicillin-Resistant Staphylococcus aureus Infections in Pediatrics. Pediatric Drugs 10:6, 367-378
CrossRef241
A. Kumar. (2008) Daptomycin versus Standard Therapy for Bacteremia and Endocarditis Caused by Staphylococcus aureus. Yearbook of Critical Care Medicine 2008, 140-142
CrossRef242
Carlos Pigrau, José Barberán. (2008) Infecciones de piel y partes blandas por grampositivos multirresistentes. Enfermedades Infecciosas y Microbiología Clínica 26, 21-30
CrossRef243
José Ramón Azanza, Emilio García-Quetglas, Belén Sádaba. (2008) Efectos adversos e interacciones de los nuevos antibióticos activos frente a cocos grampositivos. Enfermedades Infecciosas y Microbiología Clínica 26, 69-76
CrossRef244
Burke A. Cunha, Vitaliy Krol, Visali Kodali. (2008) Methicillin-resistant Staphylococcus aureus (MRSA) mitral valve acute bacterial endocarditis (ABE) in a patient with Job’s syndrome (hyperimmunoglobulin E syndrome) successfully treated with linezolid and high-dose daptomycin. Heart & Lung: The Journal of Acute and Critical Care 37:1, 72-75
CrossRef245
Gregory Martin Metz, Ananth Thyagarajan. (2008) A SUCCESSFUL PROTOCOL FOR DAPTOMYCIN DESENSITIZATION. Annals of Allergy, Asthma & Immunology 100:1, 87
CrossRef246
Thiago Lisboa, Jordi Rello. (2008) Neumonía nosocomial por grampositivos. Enfermedades Infecciosas y Microbiología Clínica 26, 53-60
CrossRef247
Robert Sauermann, Markus Rothenburger, Wolfgang Graninger, Christian Joukhadar. (2008) Daptomycin: A Review 4 Years after First Approval. Pharmacology 81:2, 79-91
CrossRef248
Jaime Fergie, Kevin Purcell. (2008) The Treatment of Community-Acquired Methicillin-Resistant Staphylococcus aureus Infections. The Pediatric Infectious Disease Journal 27:1, 67-68
CrossRef249
Daniel J.G. Thirion, David Williamson, Natacha Chaumard, Pierre Martineau, Murray P. Ducharme. 2008. Traitement de l'endocardite bactérienne. , 1041-1059.
CrossRef250
Ilker Uçkay, Stephan Harbarth, Didier Pittet. (2007) Management of Gram-positive bacteraemia. Current Opinion in Infectious Diseases 20:6, 561-567
CrossRef251
Robert C Owens. 2007. Antimicrobial Stewardship: Rationale for and Practical Considerations of Programmatic Institutional Efforts to Optimize Antimicrobial Use. , 261-300.
CrossRef252
Heather C. Yun, Michael W. Ellis, James H. Jorgensen. (2007) Activity of ceftobiprole against community-associated methicillin-resistant Staphylococcus aureus isolates recently recovered from US military trainees. Diagnostic Microbiology and Infectious Disease 59:4, 463-466
CrossRef253
Pamela A. Moise, George Sakoulas. 2007. Staphylococcus aureus: Resistance Update and Treatment Options. , 75-88.
CrossRef254
Cindy A Loffler, Conan MacDougall. (2007) Update on prevalence and treatment of methicillin-resistant Staphylococcus aureus infections. Expert Review of Anti-infective Therapy 5:6, 961-981
CrossRef255
J. R. Lentino, M. Narita, V. L. Yu. (2007) New antimicrobial agents as therapy for resistant gram-positive cocci. European Journal of Clinical Microbiology & Infectious Diseases 27:1, 3-15
CrossRef256
Patricia Dandache, Wilbert S. Aronow, George Sakoulas. (2007) Clinical Update on the Diagnosis and Treatment of Bacterial Endocarditis. Comprehensive Therapy 33:4, 192-207
CrossRef257
Riccardo Utili, Emanuele Durante-Mangoni, Marie-Françoise Tripodi. (2007) Infection of intravascular prostheses: how to treat other than surgery. International Journal of Antimicrobial Agents 30, 42-50
CrossRef258
Samir S. Awad, Saleem I. Elhabash, Liz Lee, Buckmister Farrow, David H. Berger. (2007) Increasing incidence of methicillin-resistant Staphylococcus aureus skin and soft-tissue infections: reconsideration of empiric antimicrobial therapy. The American Journal of Surgery 194:5, 606-610
CrossRef259
Christoph K. Naber, Raimund Erbel. (2007) Infective endocarditis with negative blood cultures. International Journal of Antimicrobial Agents 30, 32-36
CrossRef260
Ian M. Gould. (2007) MRSA bacteraemia. International Journal of Antimicrobial Agents 30, 66-70
CrossRef261
Barry I Eisenstein. (2007) Use of daptomycin for treatment of Staphylococcus aureus infections. Expert Opinion on Drug Discovery 2:11, 1523-1536
CrossRef262
Burke A. Cunha, Nardeen Mickail, Lawrence Eisenstein. (2007) E. faecalis vancomycin-sensitive enterococcal bacteremia unresponsive to a vancomycin tolerant strain successfully treated with high-dose daptomycin. Heart & Lung: The Journal of Acute and Critical Care 36:6, 456-461
CrossRef263
Markku Toivonen. (2007) How bacteraemia is reviewed by medicines licensing authorities in Europe. International Journal of Antimicrobial Agents 30, 103-107
CrossRef264
Christina Kratzer, Werner Rabitsch, Alexander M. Hirschl, Wolfgang Graninger, Elisabeth Presterl. (2007) In vitro activity of daptomycin and tigecycline against coagulase-negative staphylococcus blood isolates from bone marrow transplant recipients. European Journal of Haematology 79:5, 405-409
CrossRef265
Hisham Ziglam. (2007) Daptomycin and tigecycline: a review of clinical efficacy in the antimicrobial era. Expert Opinion on Pharmacotherapy 8:14, 2279-2292
CrossRef266
Evelina Tacconelli, Maria A Cataldo. (2007) Antimicrobial therapy of Staphylococcus aureus bloodstream infection. Expert Opinion on Pharmacotherapy 8:15, 2505-2518
CrossRef267
E. E. Hill, S. Vanderschueren, J. Verhaegen, P. Herijgers, P. Claus, M.-C. Herregods, W. E. Peetermans. (2007) Risk Factors for Infective Endocarditis and Outcome of Patients With Staphylococcus aureus Bacteremia. Mayo Clinic Proceedings 82:10, 1165-1169
CrossRef268
S. T. Micek. (2007) Alternatives to Vancomycin for the Treatment of Methicillin-Resistant Staphylococcus aureus Infections. Clinical Infectious Diseases 45:Supplement 3, S184-S190
CrossRef269
Linda K. Shipton, Satish Pillai, Howard Gold, Christopher McCoy, James E. Kirby, Adolf W. Karchmer, George Eliopoulos, Sonia N. Chimienti. (2007) Experience With Daptomycin in Staphylococcus Bone and Joint Infections. Infectious Diseases in Clinical Practice 15:5, 324-329
CrossRef270
David A. Enoch, Jeanine M. Bygott, Marie-Louise Daly, J. Andreas Karas. (2007) Daptomycin. Journal of Infection 55:3, 205-213
CrossRef271
H. W. Boucher, G. Sakoulas. (2007) Perspectives on Daptomycin Resistance, with Emphasis on Resistance in Staphylococcus aureus. Clinical Infectious Diseases 45:5, 601-608
CrossRef272
Kyle J. Popovich, Bala Hota, Robert A. Weinstein. (2007) Treatment of community-associated methicillin-resistant Staphylococcus aureus. Current Infectious Disease Reports 9:5, 398-407
CrossRef273
Ian Jenkins. (2007) Linezolid- and vancomycin-resistantEnterococcus faecium endocarditis: Successful treatment with tigecycline and daptomycin. Journal of Hospital Medicine 2:5, 343-344
CrossRef274
P.M. Olaechea Astigarraga, J. Garnacho Montero, S. Grau Cerrato, O. Rodríguez Colomo, M. Palomar Martínez, R. Zaragoza Crespo, P. Muñoz García-Paredes, E. Cerdá Cerdá, F. Álvarez Lerma. (2007) Recomendaciones GEIPC-SEIMC y GTEI-SEMICYUC para el tratamiento antibiótico de infecciones por cocos grampositivos en el paciente crítico. Enfermedades Infecciosas y Microbiología Clínica 25:7, 446-466
CrossRef275
Douglas J. Biedenbach, Jan M. Bell, Helio S. Sader, Thomas R. Fritsche, Ronald N. Jones, John D. Turnidge. (2007) Antimicrobial susceptibility of Gram-positive bacterial isolates from the Asia–Pacific region and an in vitro evaluation of the bactericidal activity of daptomycin, vancomycin, and teicoplanin: a SENTRY Program Report (2003–2004). International Journal of Antimicrobial Agents 30:2, 143-149
CrossRef276
Daum, Robert S., . (2007) Skin and Soft-Tissue Infections Caused by Methicillin-Resistant Staphylococcus aureus. New England Journal of Medicine 357:4, 380-390
Full Text277
Thomas P Lodise, Peggy S McKinnon. (2007) Burden of Methicillin-Resistant Staphylococcus aureus : Focus on Clinical and Economic Outcomes. Pharmacotherapy 27:7, 1001-1012
CrossRef278
B. Plicht, C.K. Naber, R. Erbel. (2007) Behandlung und Diagnostik infektiöser Endokarditiden mit negativen Blutkulturbefunden. Der Kardiologe 1:1, 35-42
CrossRef279
Florian Weis, Andres Beiras-Fernandez, Ingo Kaczmarek, Ralf Sodian, Calin Vicol, Bruno Reichart, Marion Weis. (2007) Daptomycin for Eradication of a Systemic Infection With a Methicillin-Resistant-Staphylococcus Aureus in a Biventricular Assist Device Recipient. The Annals of Thoracic Surgery 84:1, 269-270
CrossRef280
Elias Abrutyn, Christopher H. Cabell, Vance G. Fowler, Bruno Hoen, José M. Miro, Carlos A. Mestres, Daniel J. Sexton, G. Ralph Corey. (2007) Medical treatment of endocarditis. Current Infectious Disease Reports 9:4, 271-282
CrossRef281
S. Deresinski. (2007) Counterpoint: Vancomycin and Staphylococcus aureus--An Antibiotic Enters Obsolescence. Clinical Infectious Diseases 44:12, 1543-1548
CrossRef282
J. F. Mohr, B. E. Murray. (2007) Point: Vancomycin Is Not Obsolete for the Treatment of Infection Caused by Methicillin-Resistant Staphylococcus aureus. Clinical Infectious Diseases 44:12, 1536-1542
CrossRef283
Henry F Chambers, Sharath S Hegde. (2007) Combating the growing problem of methicillin-resistant Staphylococcus aureus : do the newer antibiotics represent a better alternative to vancomycin?. Expert Review of Anti-infective Therapy 5:3, 333-335
CrossRef284
Stan Deresinski. (2007) Vancomycin: does it still have a role as an antistaphylococcal agent?. Expert Review of Anti-infective Therapy 5:3, 393-401
CrossRef285
Christoph K. Naber, Raimund Erbel, Larry M. Baddour, Dieter Horstkotte. (2007) New guidelines for infective endocarditis: a call for collaborative research. International Journal of Antimicrobial Agents 29:6, 615-616
CrossRef286
Graeme N Forrest. (2007) PNA FISH: present and future impact on patient management. Expert Review of Molecular Diagnostics 7:3, 231-236
CrossRef287
Sushrut S Waikar, Kathleen D Liu, Glenn M Chertow. (2007) The incidence and prognostic significance of acute kidney injury. Current Opinion in Nephrology and Hypertension 16:3, 227-236
CrossRef288
Abhijit M. Bal, Ian M. Gould. (2007) Empirical antimicrobial treatment for chemotherapy-induced febrile neutropenia. International Journal of Antimicrobial Agents 29:5, 501-509
CrossRef289
A.L. Casey, P.A. Lambert, T.S.J. Elliott. (2007) Staphylococci. International Journal of Antimicrobial Agents 29, S23-S32
CrossRef290
Zeina A Kanafani, G Ralph Corey. (2007) Daptomycin: a rapidly bactericidal lipopeptide for the treatment of Gram-positive infections. Expert Review of Anti-infective Therapy 5:2, 177-184
CrossRef291
Emma J Bishop, Benjamin P Howden. (2007) Treatment of Staphylococcus aureus infections: new issues, emerging therapies and future directions. Expert Opinion on Emerging Drugs 12:1, 1-22
CrossRef292
Elijah Paintsil. (2007) Pediatric community-acquired methicillin-resistant Staphylococcus aureus infection and colonization: trends and management. Current Opinion in Pediatrics 19:1, 75-82
CrossRef293
Garyphallia Poulakou, Helen Giamarellou. (2007) Investigational treatments for postoperative surgical site infections. Expert Opinion on Investigational Drugs 16:2, 137-155
CrossRef294
D.R. Snydman. (2007) Daptomycin versus Standard Therapy for Bacteremia and Endocarditis Caused by Staphylococcus aureus. Yearbook of Medicine 2007, 78-80
CrossRef295
Philip I Hair, Susan J Keam. (2007) Daptomycin. Drugs 67:10, 1483-1512
CrossRef296
Craig A. Hutton, Matthew A. Perugini, Juliet A. Gerrard. (2007) Inhibition of lysine biosynthesis: an evolving antibiotic strategy. Molecular BioSystems 3:7, 458
CrossRef297
Jennifer Le, Jay M Lieberman. (2006) Management of Community-Associated Methicillin-Resistant Staphylococcus aureus Infections in Children. Pharmacotherapy 26:12, 1758-1770
CrossRef298
Marci Drees, Helen Boucher. (2006) New agents for Staphylococcus aureus endocarditis. Current Opinion in Infectious Diseases 19:6, 544-550
CrossRef299
A. W. Karchmer. (2006) From theory to practice: resistance in Staphylococcus aureus and new treatments. Clinical Microbiology and Infection 12:s8, 15-21
CrossRef300
R. Finch. (2006) Gram-positive infections: lessons learnt and novel solutions. Clinical Microbiology and Infection 12:s8, 3-8
CrossRef301
B. Wiedemann. (2006) Test results: characterising the antimicrobial activity of daptomycin. Clinical Microbiology and Infection 12:s8, 9-14
CrossRef302
William J. Martone, Kenneth C. Lamp. (2006) Efficacy of daptomycin in complicated skin and skin-structure infections due to methicillin-sensitive and ‐resistant Staphylococcus aureus : results from the CORE Registry*. Current Medical Research and Opinion 22:12, 2337-2343
CrossRef303
H. S. M. Ammerlaan, M. J. M. Bonten. (2006) Daptomycin: graduation day. Clinical Microbiology and Infection 12:s8, 22-28
CrossRef304
(2006) Therapy for Methicillin-Resistant Staphylococcus aureus. New England Journal of Medicine 355:20, 2153-2155
Full Text305
Javier Garau. (2006) Management of cSSTIs:the role of daptomycin. Current Medical Research and Opinion 22:11, 2079-2087
CrossRef306
Jacyntha A. Sterling. (2006) Hospital Pharmacy Pulse - Recent Publications on Medications and Pharmacy. Hospital Pharmacy 41:11, 1122-1128
CrossRef307
Alan Johnson. (2006) Daptomycin in the treatment of skin, soft-tissue and invasive infections due to Gram-positive bacteria. Future Microbiology 1:3, 255-265
CrossRef308
Grayson, M. Lindsay, . (2006) The Treatment Triangle for Staphylococcal Infections. New England Journal of Medicine 355:7, 724-727
Full Text
- Letters
